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NOVEL TRANSLATIONAL REGULATION OF THE PROAPOPTOTIC BCL2 
MEMBER PUMA AND ITS ROLE DURING SKELETAL MYOBLAST 
APOPTOSIS 
ATOSSA SHALTOUKI 
 
 
ABSTRACT 
 
 Differentiation and apoptosis are coordinately regulated in skeletal myoblasts.  
During the process of skeletal myoblast differentiation, our lab has determined 
that roughly 30% of myoblasts undergo apoptosis rather than differentiation. 
Further, we have reported that cytochrome C is released, and that the expression 
level of the pro-apoptotic Bcl2 family member PUMA is elevated, when 23A2 
myoblasts are cultured in DM. Our long-term goal is to identify targets for 
manipulation that would abrogate this apoptosis without affecting differentiation. 
These findings could be significant to the study of myoblast transfer as a 
therapeutic approach. 
 
 The goals of this dissertation are to:  
1- determine the significance of PUMA in apoptosis associated with skeletal 
myoblast differentaion  
2- determine the mechanism responsible for the increased expression of 
PUMA  
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 In chapter II, we provide the data documenting that the release of cytochrome C 
in 30% of 23A2 cells correlates with the percentage of the cells undergoing 
apoptosis. We also showed that suppression of PUMA expression using short 
hairpin interfering RNA-mediated silencing of PUMA decreased the release of 
cytochrome C and apoptosis in 23A2 cells, thus demonstrating that the increased 
expression of PUMA is critical for the apoptotic process.  Abrogation of PUMA 
expression did not affect that ability of myoblasts to undergo differentiation. Using 
a p53 pharmacological inhibitor Pifithrin, we showed that signaling through p53 is 
not responsible for the increased expression of PUMA in DM. Finally, using a 
fibroblast cell line expressing an estrogen receptor:MYoD fusion protein, we have 
determined that addition of estradiol sensitizes these fibroblasts to apoptosis and 
results in increased PUMA expression.  
 
In chapter III, we have determined that culturing of myoblasts in DM with 
actinomyocin D is sufficient to block the increase in PUMA mRNA levels, but 
does not prevent the increase in PUMA protein levels.  Further, metabolic 
labeling of newly synthesized proteins in myoblasts cultured in either growth 
media (GM) or DM supplemented with actinomycin D followed by 
immunoprecipitation of PUMA has allowed us to conclude that this increase in 
PUMA protein is a consequence of increased translation. Polyribosome analysis 
of PUMA mRNA indicated that translational regulation most probably occurs at 
the initiation step.  We have also found that the increase in PUMA protein levels 
occurs under conditions of eIF2 alpha phosphorylation and subsequent global 
 x 
 
decrease in total protein synthesis.  Analysis of the 5’ UTR of PUMA mRNA by 
Mfold program predicts stable secondary structures incompatible with efficient 
ribosome scanning. Further, we have determined that impairment of cap-
dependent translation in vitro and in vivo did not affect the translation of PUMA 
mRNA. Finally, we have generated data indicating that the increased translation 
of PUMA in DM is mediated by an internal ribosome entry site (IRES). Using 
mono- and bi-cistronic reporters, we have identified a fragment of PUMA mRNA 
that allows for cap-independent translation in vitro and in vivo in response to 
culture in DM. This fragment encompasses regions upstream and downstream of 
the initiation AUG codon. Thus, our data indicate that increased expression of 
PUMA in skeletal myoblasts relies on IRES-meditated translation. 
 
In summary, we identified PUMA as the BH3-only proapoptotic molecule that 
plays an essential role in the apoptosis but not the differentiation of skeletal 
myoblasts. Thus, we have identified PUMA as a potential target for therapeutic 
manipulation to abrogate apoptosis without affecting differentiation. Finally we 
identified that IRES-mediated translation of PUMA as the mechanism responsible 
for the increase in PUMA expression in response to different stress stimuli.  
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CHAPTER I 
 
INTRODUCTION 
 
The skeletal myoblast model system 
   Skeletal muscle is a valuable model for studying the mechanisms and 
signaling pathways that regulate cell lineage specification and differentiation. The 
myogenic  program requires a group of transcription factors belonging to the 
muscle regulatory transcription factor (MRF) family consisting of Myf-5, MyoD, 
myogenin and MRF4 (1-6).  Each member of the family shares a region of 
homology consisting of a basic region followed by a Helix loop Helix motif 
important for its protein oligomerization and DNA binding properties (7-9). Further 
(8-10) each factor is capable of inducing muscle lineage upon its expression in 
nonmuscle cells (2-4, 11). Examination of MRF expression patterns in the 
embryo as well as in muscle cell lines has revealed a temporal and spatial 
expression pattern for each MRF member with MyoD and Myf-5 being expressed 
in proliferating myoblasts and Myogenin and MRF4 being expressed upon 
differentiation (12-14).  MyoD was the first member of MRFs identified and has 
been the most studied (8).    
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Detailed understanding of the mechanistic regulation of myogenesis has 
come from in vitro studies using murine myoblast cell lines.  The myoblast cell 
lines most widely used are either isolated from C3H mice (C2C12 and BC3H-1) 
or derived from non-specified 10T1/2 fibroblasts also from C3H mice (23A2 
myblasts) (15, 16). In vivo, circulating mitogens maintain myoblasts in an actively 
dividing and undifferentiated state.  Appropriate migration results in a decrease in 
available mitogens, activation of MyoD, withdrawal from cell cycle and 
subsequent differentiation.  
 
In proliferating myoblasts, MyoD is constitutively expressed but is 
transcriptionally inactive (2, 11, 17, 18). Transcriptional activation by MyoD 
requires dimerization with E-protein members through basic helix-loop-helix 
(bHLH) domain to form a heterodimeric complex capable of binding a DNA 
consensus sequence: CANNTG which is known as E-box elements within the 
regulatory regions of most muscle-specific genes (7, 19, 20).  In the presence of 
serum growth factors expression levels of Id remain high. Id is a HLH protein that 
lacks the basic region.  Id heterodimerization with E-proteins prevents their 
binding to MyoD.  In the absence of serum, Id proteins are degraded and 
differentiation is achieved upon MyoD transcriptional activation (21-23).  The in 
vitro differentiation of skeletal myoblasts can thus be induced by mitogen 
withdrawal.  Our lab (24) and others (25, 26) have previously reported that, in 
response to mitogen withdrawal, approximately 70% of myoblasts undergo 
differentiation while 30% will undergo apoptosis.  The apoptotic process in other 
 3 
 
cell systems has been studied extensively. The goal of the Weyman’s lab has 
been to understand the functional apoptotic pathways in skeletal myoblasts.  
 
 Overview of Apoptosis 
  Apoptosis is a programmed cell death that occurs during normal 
development and is also important for maintaining tissue homeostasis (27). 
During development, maintaining the proper number of cells within a given tissue 
is achieved by a balance between proliferation and cell death.  This ability of the 
cell to “commit suicide” in any tissue when no longer necessary, damaged or 
when lacking a survival factor is an active process and requires activation of 
certain conserved apoptotic genes (28, 29). Apoptosis has been implicated in the 
deletion of excess cells during myogenesis (30, 31), in the central nervous 
system (32), and in the removal of self-reactive T cells  in the immune response 
(33) as well as during limb formation (34) and metamorphosis (29).  Cells with 
damaged genetic content are also known to undergo the apoptotic process.   
Programmed cell death is a highly regulated process and therefore its 
disregulation is associated with a variety of diseases such as cancer (which is 
the case of too little apoptosis) or autoimmune disease (excessive apoptosis) 
(35). Cells undergoing programmed cell death exhibit a characteristic of a 
condensed cytoplasm and nucleus in addition to chromatin aggregation. 
Apoptosis is characterized by the production of apoptotic bodies, plasma 
membrane blebbing and the generation of nuclear DNA fragments of 
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internucleosomal size (36, 37). These morphological changes associated with 
apoptosis are achieved by a family of proteases known as caspases.  
 
 Caspases  
Caspases are cysteine-aspartic acid specific proteases that catalyze the 
cleavage of their substrate after Aspartic Acid residues by their cysteine-rich 
active sites (28, 38). In every cell, caspases are made as inactive proenzymes 
consisting of a small and a large subunit and an N-terminus prodomain of 
variable length important for their recruitment and activation.  Signaling events 
that lead to proteolysis between the subunits and removal of the prodomain,  
result in formation of active caspases which are a heterotetramer of 2 small and 
2 large subunits of two procaspase molecules. Caspases are divided into two 
groups based on the size of their prodomains; the “initiator caspases” (caspase 
2, 8, 9 and 10) have a long N-terminal prodomain while the “executioner 
caspases” (caspase 3, 6 and 7) have a short prodomain.  Subclassification of 
initiator caspases based on their mode of activation divides this group of 
caspases further into two groups. Caspases 2 and 8 have a long prodomain 
containing a death effector domain (DED), while caspase 9 has a caspase 
recruitment domain (CARD). In general, activation of initiator caspases by 
internal or external cues initiates a caspase cascade reaction,  activating the 
downstream executioner caspases and leading to destruction of the cell (28, 39, 
40). Two signaling pathways have been implicated in the initiation of apoptosis: 
the extrinsic pathway and the intrinsic pathway (41, 42) 
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 The intrinsic pathway   
  The internal pathway of apoptosis begins with the mitochondria in 
response to a wide range of stimuli such as DNA damage, ER stress, oxidative 
stress, serum deprivation and other death inducing signals and results in 
mitochondrial outer membrane permeabilization (MOMP).  MOMP results in the 
release of pro-apoptotic proteins, such as cytochrome C (43), Smac/Diablo 
(second mitochondria-derived activator of caspase/ direct IAP-binding protein 
with low pI) (44), omi/HtrA2 (high temperature requirement protein A2) (45, 46)  
and  EndoG (Endonuclease G) (47, 48) from the intermembrane space of the 
mitochondria (49).  After the release of cytochrome C from the mitochondria, a 
caspase  cascade is initiated (50-52).  In the cytosol, binding of cytochrome C 
with a WD-40 repeat of Apaf-1 (apoptotic protease activating factors) in an ATP 
dependent manner causes a conformational change and hepamerization of Apaf-
1. A multiprotein complex known as apoptosome is then formed which 
participates in initiating the recruitment and activation of procaspase 9. Activation 
of caspase 9 within the apoptosome complex leads to cleavage and activation of 
downstream caspases 3 and 7 (53-55). In the cytosol, activity of caspases 3, 7 
and 9 can be further inhibited by cytosolic cIAPs (cellular inhibitor of apoptosis), a 
family of proteins with antiapoptotic activity originally identified in the genome of 
baculovirus (56). The binding of caspases to the conserved baculovirus IAP 
repeat (BIR) domain of cIAPs inhibits apoptosis (57). However, this inhibition of 
caspase activity is relieved by the release of mitochondrial proteins such as 
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Smac/Diablo and Omi/HrtA, two mammalian IAP-binding proteins (58-61) (Fig. 
1). 
 
The extrinsic pathway 
  The external pathway of apoptosis involves the activation of death 
receptors belonging to the tumor necrosis factor receptor superfamily (TNFR) 
(62, 63) in response to external stimuli resulting directly in caspase activation. 
The cytoplasmic regions of these death receptors (TNFR-1, Fas/CD95, TRAIL 
DR4, DR5) consist of death domains while the extracellular region is cysteine 
rich and allows trimerization and activation of the receptor by its ligand (64, 65). 
Upon binding of a death ligand to its receptor, procaspase- 8 is recruited to the 
death receptor through binding to death effector domains of adaptor proteins like 
FADD or TRADD in the death inducing signaling complex (DISC). Once several  
procaspase 8 molecules are recruited to the DISC complex,  then by virtue of 
close proximity they cleave and activate each other through a process known as 
autoproteolysis. Activation of caspase 8 molecules leads to a caspase cascade 
resulting in the activation of effector caspases 3, 6, and 7 (40).  Activation of 
caspase 8 has also been implicated in mitochondrial mediated cell death. It has 
been shown that caspase 8 cleaves Bid, a BH3-only member of the Bcl2 family, 
and that truncated Bid can translocate to the mitochondia and induce the release 
of cytochrome C via activation of Bax and Bak (66) (Fig. 2). 
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Figure 1.1 The Intrinsic Pathway of Apoptosis. In the presence of 
serum, PI3K phosphorylates the proapoptotic member Bad resulting in 
the cytosolic localization of Bad through its interaction with scaffold 
protein 14-3-3. In the absence of serum, the PI3K signaling pathway is 
inactive. Bad translocates to the mitochondria where it binds and blocks 
the activity of the antiapoptotic Bcl2 members. In response to DNA 
damage, the expression of BH3-only members like Bax and PUMA is 
upregulated in a p53-dependent manner. These proteins can then 
translocate to the mitochondria and cause permeabilization of the 
mitochondial membrane and the release of cytochrome C and other 
antiapoptotic molecules from the mitochondria. Cytochrome C binds 
Apaf-1 and caspase 9 resulting in apoptosome formation. Caspase 9 is 
active in the apoptosome and cleaves and activates caspases 3, 7 and 
downstream cellular targets. 
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Figure 1.2 The Extrinsic Pathway of Apoptosis Activation of the 
extrinsic pathway begins with the binding of a death ligand to its 
receptor which causes oligomerization of the receptors. Adaptor 
proteins such as FADD (Fas-associated death domain) are recruited to 
intracellular domains of these receptors which are known as the “Death 
domains”, forming the death-inducing signaling complex (DISC). 
Initiator caspases 8 and 10 are recruited to DISC through their death 
effector domains and are self-cleaved and activated by virtue of close 
proximity. Activated caspases 8 and 10 can then cleave and activate 
downstream caspases 3, 6, and 7.  The intrinsic arm of this pathway 
involves the cleavage of pro-apoptotic Bcl2 member Bid by caspase 8. 
Truncated Bid translocates to the mitochondria and dimerizes with Bax, 
converging on the intrinsic pathway. 
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Bcl2 Family  
  The release of cytochrome C is subject to regulation by the Bcl-2 family of 
proteins (67).  Bcl2 (B cell lymphoma 2) was the first member of the family 
identified as a proto-oncogene in follicular lymphoma cells with the t(14:18) 
chromosome translocation involving heavy chain joining regions of the 
immunoglobulin heavy chain locus on chromosome 14 and the bcl-2 gene on 
chromosome 18 (68). Many members of this protein family have a C-terminal 
transmembrane domain important for membrane docking (69). The involvement 
of the Bcl2 protein family in the apoptotic process came from genetic studies in 
C. elegans. These studies showed that the product of the ced9 gene, a homolog 
of mammalian Bcl2, is essential in preventing programmed cell death during 
worm development (70). Anti-apoptotic members of the Bcl-2 family (Bcl-2, Bcl-
xL, Bcl-w, A-1/Bfl-1 and Mcl-1, E1B, BHRF1, CED9) prevent mitochondrial 
disruption while pro-apoptotic members of the Bcl-2 family initiate mitochondrial 
disruption (60, 71-73).  Sequence homology among members of Bcl-2 family has 
identified regions of high homology (BH1 to BH 4) important for protein-protein 
interaction. All anti-apoptotic members of the Bcl-2 family contain all four BH 
domains (Bcl2 homology domain) (74). Deletion of the BH4 domain has shown to 
promote pro-apoptotic activity in anti-apoptotic members of Bcl-2 family, 
indicating that this BH4 domain is essential for prosurvival activity of these 
members (69, 75).  All proapoptotic members of Bcl2 lack this BH4 domain but 
must contain at least one BH3 domain. Classification of the pro-apoptotic 
members are either multi-domain (Bax,  Bak and Bok/Mtd) or BH3-only domain 
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(Bid, Bim, Bik, Bad, Bmf, Hrk, Noxa, PUMA, Blk, BNIP3 and Spike) (76, 77).  The 
primary function of the BH3 only family members is to induce the activation of 
Bax or Bak (78, 79) or to inhibit the anti-apoptotic function of Bcl-2 members (80). 
Knockout studies have demonstrated that both Bax and Bak are important 
regulators of mitochondia-mediated cell death since inactivation of both Bax and 
Bak in mice resulted in decreased apoptosis in different tissues during 
development. In addition, cells derived from these double knockout mice have 
been shown to be resistant to apoptosis in response to many stress stimuli (81, 
82).  In the absence of death signals, Bax exists as a monomer loosely 
associated with the membrane in the cytosol while Bak is located at the 
mitochondria.  Following death signals, Bax and Bad undergo conformational 
changes that allow them to insert into the outer mitochondrial membrane and 
oligomerize (83), resulting in permeablization of the outer mitochondial 
membrane and release of proapoptotic proteins. It has been postulated that 
interaction with BH3 only members of the Bcl-2 family contributes to the 
oligomerization and channel forming ability of multidomain Bax and Bak while 
antiapoptotic members prevent this (83, 84). Alternatively, the increase in 
mitochondrial outer membrane permeability (MOMP) associated with the intrinsic 
apoptotic pathway can involve a sudden increase in permeability of the inner 
mitochondrial membrane to molecules up to 1.5 Kda, which result in 
mitochondrial swelling and rupture of outer mitochondrial membrane. The 
induction of mitochondrial permeability transition (MTP) through formation of the 
mitochondrial permeability transition pore (PTP) can be achieved by various 
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stimuli. PTP complexes consist of the ANT protein (adenine nucleotide 
translocator) in the inner mitochondrial membrane, the VDAC (voltage dependent 
anion channel) in the outer mitochondrial membrane, the benzodiazepine 
receptor and cyclophilin D (85-87). Although Bax and Bak are not essentional for 
MTP induction, interaction of Bax with VDAC and ANT has been reported to 
cause MOMP (88, 89). 
 
Skeletal myoblast apoptosis 
  Apoptosis has been observed in cultures of primary myoblasts, 
established muscle cell lines, and in vertebrate models during the process of 
differentiation (24-26, 30, 31).  Molecular mechanisms responsible for regulating 
apoptosis in skeletal muscle are still emerging. In skeletal myoblasts, a 
correlation between CDK inhibitor p21 induction and an apoptosis-resistance 
phenotype has been established (26).  Our lab has previously reported that a 
delay of apoptosis can be achieved by the pharmacological inhibition of caspase 
3 activity (24) and that the apoptosis associated with differentiation is abrogated 
by activated Ras or Raf signaling (90, 91).  Over-expression of MyoD has been 
reported to be pro-apoptotic in cell lines lacking functional retinoblastoma protein 
(Rb) through expression of SV40 large T (92).  Our lab has determined that 
activated Ras-mediated increased survival of myoblasts correlates with 
decreased levels of MyoD expression (93).  Taken together, these data suggest 
a novel pro-apoptotic role for MyoD. Specifically, our data suggest that 
endogenous levels of MyoD can confer the ability to undergo apoptosis in cells 
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with functional Rb. We have further determined that culture in DM results in 
increased levels of the pro-apoptotic Bcl2 family member PUMA and the release 
of cytochrome C from the mitochondria (94). This increase in PUMA expression 
can still be detected in the absence of increased levels of PUMA mRNA 
(Shaltouki, manuscript in prepration). Thus, the Aims of my dissertation are to  
 
1- determine the ability of MyoD to induce the expression of PUMA and 
apoptosis 
2-  determine the significance of PUMA to the release of cytochrome C from the  
mitochondria and apoptosis 
3- investigate general translational regulation during myogenesis and explore 
translational regulation as the mechanism responsible for the increased 
expression of PUMA 
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CHAPTER II 
 
INCREASED EXPRESSION OF THE PRO-APOPTOTIC BCL2 FAMILY 
MEMBER 1PUMA IS REQUIRED FOR MITOCHONDRIAL RELEASE OF 
CYTOCHROME C AND THE APOPTOSIS   ASSOCIATED WITH SKELETAL 
MYOBLAST DIFFERENTIATION 
 
                                            
 The data in this chapter is included in two separate manuscripts entitled “ Increased expression of the pro-
apoptotic  BCL2 family member PUMA is required for mitochondrial release of cytochrome C and the 
apoptosis associated with skeletal myoblast differentiation.” Shaltouki, A., Freer, M., Mei. Y., Weyman, 
C.M.,  Apoptosis.Dec. 2007, and “ Increased expression of the pro-apoptotic Bcl2 family member PUMA 
and apoptosis by the muscle regulatory transcription factor MyoD in response to a variety of stimuli” 
Harford, T. J., Shaltouki, A. Weyman, C.M., Apoptosis 2009 in press. 
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ABSTRACT 
We have previously shown that when skeletal myoblasts are cultured in 
differentiation medium (DM), roughly 30% undergo caspase 3-dependent 
apoptosis rather than differentiation. Herein, we demonstrate that culturing 23A2 
myoblasts in DM results in a time dependent release of mitochondrial 
cytochrome C into the cytosol in roughly 30% of myoblasts.  Additionally, it has 
been shown previously in our lab that inclusion of cycloheximide inhibits the 
release of cytochrome C, the activation of caspase 9 and apoptosis.  These data 
indicate that the mitochondrial pathway plays a role in this apoptotic process and 
that engagement of this pathway relies on de novo protein synthesis.  Through 
RT-PCR and immunoblot analysis, we have  determined that the expression level 
of the pro-apoptotic Bcl2 family member PUMA is elevated when 23A2 myoblasts 
are cultured in DM.  Using shRNA against PUMA, we show that the silencing of 
PUMA inhibits the release of cytochrome C and apoptosis.  Furthermore, 
signaling by the transcription factor p53 is not responsible for the increased level 
of PUMA.  We also provide evidence that myoblasts rescued from apoptosis by 
either inhibition of elevated caspase 9 activity or silencing of PUMA are 
competent for differentiation.  These results indicate a critical role for PUMA in 
the apoptosis associated with skeletal myoblast differentiation and that a p53-
independent mechanism is responsible for the increased expression of PUMA in 
these cells. Finally, we demonstrate that MyoD activation can induce the 
expression of PUMA, cytochrome C release and apoptosis, supporting our 
previous finding that MyoD expression levels correlate with apoptosis. 
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INTRODUCTION 
Differentiation and apoptosis are coordinately regulated in many cell types 
throughout development and to maintain homeostasis.  During the process of 
skeletal myoblast differentiation, roughly 30% of myoblasts undergo apoptosis 
rather than differentiation (1, 2).  The apoptosis of myoblasts is a physiological 
process that likely serves the necessary function of removing excess myoblasts 
during muscle regeneration (3) and myogenesis (4). This coordinate regulation of 
differentiation and apoptosis could decrease the efficacy of myoblast transfer to 
treat a variety of diseases. Skeletal myoblast apoptosis also contributes 
pathologically to a variety of disease states (1, 5-12).  Elucidating the functional 
apoptotic pathways in skeletal myoblasts, therefore, will identify targets for 
therapeutic manipulation that could increase the efficacy of myoblast transfer and 
could alleviate disease states associated with muscle degeneration.   
 
Despite the vast  knowledge detailing skeletal myoblast determination and 
differentiation, our understanding of  the molecular mechanisms controlling the 
apoptosis associated with skeletal myoblast differentiation is limited (2, 13-21). 
 
The molecular mechanisms responsible for apoptosis in other systems, 
however, have been extensively studied.  In most systems, mitochondrial 
disruption and subsequent release of pro-apoptotic proteins like cytochrome C is 
a critical event in the process of apoptosis (22).  The release of these factors 
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from the mitochondria is antagonized by anti-apoptotic members of the Bcl2 
family and initiated by pro-apoptotic members.  Pro-apoptotic members can be 
activated by post-translational modification, subcellular translocation and/or by 
increased expression (22-24).  
 
 PUMA has been identified as a transcriptional target of p53 by SAGE 
analysis (25, 26) and as a Bcl2 interacting protein by a yeast two-hybrid (27). 
PUMA is a member of the BH3-only pro-apoptotic Bcl2 family sharing only a 
conserved Bcl2 homology (BH3) domain with other members of this family. Like 
other BH3-only members, PUMA localizes at the mitochondria in response to 
death signals.  At the mitochondria, PUMA heterodimerizes with multidomain 
Bcl2 family members such as Bcl-xl or Bcl-2, antagonizing their function by 
disassociating them from Bax, allowing Bax oligomerization, depolarization of the 
mitochondrial membrane potential and release of cytochrome C (28). Released 
cytochrome C interacts with the adaptor protein Apaf-1 (adaptor protease-
activating factor 1). This interaction results in a conformational change in Apaf-1 
and induces oligomerization and activation of the initiator caspase 9 in an dATP 
dependent manner and subsequent activation of caspase 3 (29).  
 
PUMA expression is regulated at the transcriptional level. Analysis of the 
PUMA promoter has identified two p53-responsive elements upstream of the  5’-
untranslated region of PUMA.  PUMA induced apoptosis in response to DNA 
damaging agents has been shown to be mediated by p53; however,  serum 
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starvation, glucocorticoids and cytokine withdrawal have been reported to induce 
PUMA expression in a p53-independent manner (25, 30, 31).  The mechanism of 
increased expression of PUMA in the absence of p53 is unknown. Recently, a 
consensus sequence corresponding to Foxo3a binding sites within the first 
intronic region of PUMA has been identified to be responsible for the increased 
expression of PUMA in response to cytokine or growth factor deprivation (32).  
 
Recently, a tumor suppressive role for PUMA has been implicated.  
PUMA-/- mice and P53-/- mice exhibit similar phenotypes and are resistant to 
stress-induced cell death stimuli such as DNA damaging agents,  oncogenic 
activation and ionizing irriadiation (31).  These reports,  along with recently 
published data showing the silencing or deregulated expression of PUMA in 
number of primary cancer cell lines, highlights the importance of PUMA as an 
emerging therapeutic target (33).  
 
Previous published data suggest a pro-apoptotic role for the muscle 
regulatory transcription factor MyoD.  Over-expressed ectopic MyoD through 
culture in differentiation media (DM) has been reported to be pro-apoptotic in cell 
lines lacking functional retinoblastoma protein (34).  Others in our laboratory 
have previously shown a correlation between MyoD expression levels and 
apoptosis in 23A2 cells. It has been demonstrated that activated Ras-mediated 
increased survival of myoblasts correlates with decreased levels of MyoD 
expression and that re-expression of endogenous levels of MyoD in these active 
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Ras-expressing cell lines restores their ability to undergo both differentiation and 
apoptosis (35).  These findings suggest that endogenous levels of MyoD might 
confer the ability to undergo apoptosis in cells with functional Rb. Therefore, we 
hypothesized that Myo D activation might be sufficient to induce the expression 
of PUMA, cytochrome C release and apoptosis. 
 
Our group has previously reported that caspase 3 plays a role in the 
apoptosis associated with differentiation in skeletal myoblasts(2). Others in our 
laboratory have shown that culturing the 23A2 myoblasts in DM results in the 
activation of caspases 9 and 3 downstream molecules of the mitochondria.  
Activation of caspase 9 requires apoptosome formation and therefore the release 
of cytochrome C from the mitochondria. In agreement with this, subcellular 
fractionation studies performed in our lab confirmed the release of cytochrome C 
into the cytosol as 23A2 myoblasts are switched from GM to DM. Reported data  
suggested that the release of cytochrome C and apoptosis in 23A2 myoblasts 
require new transcription and translation. This led to identification of the pro-
apoptotic family member PUMA whose expression increases as a consequence 
of culture in DM.  Herein, we investigate the mitochondrial disruption as a 
consequence of culture in differentiation media and identify the pro-apoptotic 
family member PUMA (p53 up-regulated modulator of apoptosis) as an additional 
contributor to this apoptotic process in skeletal myoblasts. Finally, we suggest 
that PUMA expression may be controlled by MyoD. 
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MATERIALS AND METHODS 
Cells and cell culture  
All cells were cultured on gelatin-coated plates and maintained in growth medium 
(GM), which consists of basal modified Eagle’s medium (BME), 10% fetal bovine 
serum (FBS) and a 1% combination of 10,000 I.U./ml penicillin and 10,000 g/ml 
streptomycin (1% P/S).  Differentiation was induced and monitored after 
switching cells from growth medium to differentiation medium (DM), which 
consists of BME, 1% P/S and 10% FBS (2, 17-20, 35-38).  Cells were incubated 
at 37C in 5% CO2.  23A2 myoblasts are a clonal line of determined myoblasts 
derived by 5-azacytidine conversion (39).  The caspase 9 inhibitor, z-LEHD-fmk, 
and the p53 inhibitor, pifithrin, were each dissolved in DMSO.  Cycloheximide 
(CHX) was dissolved in methanol.  Appropriate volumes of DMSO or methanol 
alone were added to control cultures and did not exceed 0.15% v/v. 
 
Total cellular, cytosolic and mitochondrial lysate preparation 
Myoblasts were plated at equal density and the next day switched to fresh GM or 
DM. For total cell lysates, cells were lysed in 1x p21 buffer (20 mM MOPS pH 
7.4, 200 mM Sucrose, 5 mM MgCl2, 0.1 mM EDTA, 1 mM DTT) containing 1% 
CHAPS, protease inhibitors (aprotinin, leupeptin, pepstatin, PMSF) and 
phosphatase inhibitors.  For cytosolic (S100) and mitochondrial (P10) lysates, 
cells were harvested by trypsinization and subjected to centrifugation at 1000xg 
for 10 minutes. The pellet was washed twice with phosphate buffered saline and 
suspended in 5 volumes of buffer A (20 mM Hepes-KOH pH 7.5, 10 mM KCL, 
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1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) containing 250 mM 
sucrose and protease inhibitors (aprotinin, leupeptin, pepstatin, PMSF).  Cells 
were homogenized by 10 strokes in a 2 ml Kontes glass Dounce homogenizer.  
Lysates were subjected to centrifugation at 750xg for 5 minutes and the resulting 
supernatant was subjected to centrifugation at 10,000xg for 15 minutes.  The 
resulting pellet was designated as the P10 fraction while the supernatant was 
subjected to centrifugation at 100,000xg for 45 minutes.  The resulting 
supernatant was designated as the S100 fraction.  All centrifugation was 
performed at 40C.  The protein concentrations of all lysates were determined 
using Coomassie Protein Assay Reagent from Pierce as per the manufacturer’s 
instructions.  
 
Analysis of cytosolic cytochrome C 
ELISA: Cytosolic cytochrome C was measured using the Quantikine M 
cytochrome C ELISA kit per manufacturer’s instructions.  Briefly, 10 g (50 l) of 
each S100 fraction was added to a well of a flat-bottomed microtiter plate pre-
coated with monoclonal anti-cytochrome C antibody.  To this, 75 l of anti-
cytochrome C antibody conjugated to horse-radish peroxidase (HRP) was added.  
After two hours rocking at room temperature, wells were washed three times 
prior to the addition of HRP substrate.  After 30 minutes, an equal volume of 
STOP solution was added and product was measured on a spectrophotometer at 
450nm.  Experiments were performed within the linear range of the assay. 
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Immunostaining 
 23A2 cells were plated at 105 cells per chamber slide and the next day switched 
to fresh GM or DM for 3 hours. Cells were then washed with PBS and fixed in 
freshly prepared formaldehyde at room temperature for 25 minutes. After 
washing three times in PBS, the fixed cells were permeabilized in 0.1% Triton X-
100 in PBS for 15 minutes prior to incubation for 30 minutes in blocking buffer 
(5% bovine serum albumin in PBS). Cells were then incubated for 4 hours either 
with a mouse monoclonal antibody against cytochrome C at 1:200 dilution 
(Pharmingen) or no antibody.  After washing three times for 10 minutes each in 
blocking buffer, the cells were incubated with a fluorescein-conjugated donky 
anti-mouse IgG (Jackson ImmunoResearch) at 1:200 for one hour. The cells 
were then washed in PBS three times at 10 minutes each followed by staining 
with 1 g/ml DAPI (Molecular Probe).  Images were acquired using a Leica TCS 
SP2 laser scanning spectral confocal microscope and analyzed using Image Pro 
Plus 5.0.  Over 250 cells from different fields were analyzed by two investigators 
without prior knowledge of sample identity. 
 
Immunostain for MHC 
23A2 cells were plated at 105 cells per chamber slide and the next day switched 
to fresh GM or DM for 48 hours.  Cells were processed and counted as above 
except that the primary antibody was MF20.  Images were visualized using an 
Olympus IX71 microscope.   
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Cytosolic nucleosome ELISA 
The presence of cytosolic nucleosomes indicative of DNA fragmentation and 
nuclear membrane disruption was used as a marker for apoptosis.  Myoblasts 
were plated at equal density and the next day switched to fresh GM or DM.  We 
have carefully correlated cell density and time in DM with the level of cytosolic 
nucleosomes and the percentage of myoblasts undergoing apoptosis.  Through 
this analysis we determined that, when myoblasts are plated at a density of 
4x105 cells per 100 mm dish, the level of cytosolic nucleosomes present after 
eight hours of culture in DM is representative of the 30% of myoblasts that finally 
undergo apoptosis (4, 23).  Thus, analysis of cytosolic nucleosomes is generally 
performed under these conditions.  Cytosolic nucleosomes were measured using 
the Cell Death Detection ELISA Plus Kit (Roche Diagnostics) as per the 
manufacturer’s instructions. Briefly, attached cells were rinsed in PBS and then 
lysed by incubation in 300 L cell lysis buffer from the kit on a rocker for 30 
minutes at room temperature. Twenty microliters of each sample was transferred 
to a 96-well, flat-bottomed, streptavidin-coated microtiter plate.  Seventy-two 
microliters of 1x incubation buffer from the kit  and 4 L each of biotin conjugated 
anti-histone antibody and peroxidase conjugated anti-DNA antibody was added 
to the lysate in the microtiter plate and incubated at 4C overnight.  Following 
three washes with 300 L of incubation buffer, the presence of cytosolic 
nucleosomes was measured by adding 100 L of the substrate, ABTS.  
Absorbance at 405 nm was measured at 60 second intervals using a 
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spectrophotometer.  Values were taken from the time point where all samples 
were within the linear range of the assay for each individual experiment.  
 
Quantitative RT-PCR  
Myoblasts were plated at equal density and the next day switched to fresh GM or 
DM with or without additional treatment.  Total RNA was prepared using 1 mL of 
Trizol (Invitrogen) reagent per plate for lysis and following the manufacturer's 
instructions.  Five hundred g of RNA was then used for a 20 L SuperScript II 
RT (Invitrogen) reverse transcription reaction.  Two L of this reaction was used 
for quantitative PCR, with 0.3 M each primer (for PUMA, forward: 
5’GTCCGCGCCCCTTCCCGCTC and Reverse: 
5’GGTGGGGCCTCCTGCCAGGG for myogenin, forward: 
5’ATGCACTGGAGTTCGGTCC and reverse: 
5’GACAGACAATCTCAGTTGGGC) and SYBR green reagent (DyNAmo, MJ  
Research) in a total of 20 L.  Fluorescence was detected using an Opticon 
Monitor (MJ Research).  The cycle number at which the amplification of product 
began linearly increasing (cycle threshold (Ct) value) was taken from the Opticon 
software and normalized as described (18).  
 
Immunoblot analysis  
Following protein determination, lysates (150 g of the S100 and P10 lysate for 
cytochrome C oxidase (COX) and 100 g of total cellular lysate for Bax, Bim, 
PUMA, MHC and myogenin) were denatured in 5x sample buffer (10% SDS, 
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50% glycerol, 10% 2-mercaptoethanol, pH 6.8) and electrophoresed through 
denaturing polyacrylamide gels (12% for COX, Bax, Bim and PUMA and 10% for 
MHC and myogenin).  Following SDS polyacrylamide gel electrophoresis (SDS-
PAGE), samples were transferred electrophoretically for four amp hours to 
Hybond-P polyvinylidene difluoride membranes in transfer buffer containing 80% 
methanol and 1 g/L SDS. Membranes were blocked for one hour in 1xTBS/0.1% 
NP40 with 10% newborn calf serum and 5% dry milk.  The following primary 
antibodies were incubated with the appropriate membranes: anti-COX antibody 
(A-6403, Molecular Probes) diluted 1:500, anti-PUMA antibody (Abcam) diluted 
1:500, anti-Bax, anti-Bim and anti-myogenin antibodies (each from 
BDPharmingen) each diluted 1:1000, anti-MHC MF20 monoclonal antibody and 
anti-actin (Sigma) diluted 1:30,000.  Appropriate HRP-conjugated secondary 
antibodies, each diluted 1:1000, were incubated with the membranes for one 
hour.  After each incubation with antibody and prior to the addition of 
chemiluminescent substrate, membranes were washed five times in 1xTBS (tris-
buffered saline pH 7.4) with 1% NP-40.  Membranes were then incubated with 
SuperSignal West Pico Chemiluminescent Substrate (Pierce) for 60 seconds and 
bands were visualized using Kodak Scientific Imaging Film. 
 
Silencing 
Lentiviral shRNA Silencing Construct - The murine PUMA-specific shRNA 
expressing lentiviral vector was purchased from OPEN Biosystems. The pLKO.1 
puro vector is ligated with a 59-mer oligonucleotide containing a hairpin of 21 
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base-pair sense and antisense stem and a 6 base-pair loop. The sequence of 
oligonucleotide was as follows (sense and antisense stem in bold, loop in 
underlined letters, restriction enzyme sites in italics and the Pol III termination 
signal in lowercase letter):  
5-
CCGGGAGGGTCATGTACAATCTCTTCTCGAGAAGAGATTGTACATGGACC
CTCttttt-3 
 
Lentiviral production and infection - The recombinant lentiviruses were produced 
by co-transfection of 293-T cells in Dulbecco’s modified Eagle’s medium 
containing 10% FBS and 1% penicillin/streptomycin with  pLKO.1-PUMA shRNA 
(or pLKO.1 puro), pCMV-VSV-G and pHR CMV-dR8.2 plasmids at a ratio of 
2:1:2 using lipofectamine 2000 (Invitrogen).  Second generation packaging 
plasmids and assistance were kindly provided by Dr. Gudkov, Lerner Research 
Institute, Cleveland, Ohio.  Lentiviral-containing supernatant was harvested at 24, 
48 and 72 hours post-transfection, 0.22 µM-filtered and snap-frozen at -70 C.  
Transduction of 23A2 cells with recombinant lentivirus was conducted in the 
presence of 10 g/ml polybrene for 12 hours. Following lentiviral infection, the 
cells were selected in 2.5 g/ml puromycin for 4 days to eliminate uninfected 
cells.  Individual puromycin resistant colonies were then isolated and propagated 
for further analysis.  PUMA levels in parental cells and in each clone were 
assessed by Western analysis.  PUMA levels did not change within each of the 
cell treatment groups through serial cell passages.  
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RESULTS 
There is a correlation between the release of cytochrome C and the 
apoptosis associated with skeletal myoblast differentiation  
We have previously reported that caspase 3 is maximally activated after 
three hours of culture in DM and that caspase 3 activity plays a role in the 
apoptosis associated with differentiation in skeletal myoblasts (2). Caspase 9 is 
an initiator caspase capable of activating caspase 3 in other systems (40).  
Others in our laboratory have shown that culturing of 23A2 myoblasts in DM 
results in activation of caspases 9 and 3, downstream molecules of mitochondria.  
It was also observed that a dose dependent, and nearly complete, inhibition of 
caspase 9 activity by LEHD-fmk corresponds to a dose dependent, albeit not 
complete, inhibition of caspase 3 activity and the ensuing apoptosis. The 
activation of caspase 9 suggested that cytochrome C had been released from the 
mitochondria (41).  Subcellular fractionation studies performed in our lab 
confirmed the release of cytochrome C from mitochondria into the cytosol as  
23A2 myoblasts are switched from GM to DM.  In addition, it was shown that the 
release of cytochrome C and apoptosis required new protein synthesis.  We have 
previously determined that 30%+/-4 of myoblasts undergo apoptosis (2). To 
determine if there is any correlation between the percentage of cells displaying 
mitochondrial release of cytochrome C and the percentage of cells undergoing 
apoptosis, we performed immunostaining analysis using confocal microscopy to 
assess the mitochondrial release of cytochrome C. Using this approach, we 
determined that 29%+/-3 of myoblasts have released mitochondrial cytochrome 
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C into the cytosol (Fig. 2.1A).  We also assessed the percentage of cells with 
altered mitochondrial membrane potential using the MitoCapture Apoptosis 
detection kit (CalBiochem) that employs a cationic dye that fluoresces red when 
aggregated in the mitochondria. In apoptotic cells, this dye fails to aggregate in 
the mitochondria due to the altered mitochondrial membrane potential and 
fluoresces green.  Using this approach, we determined that 30%+/-3 of 
myoblasts display altered mitochondrial membrane potential. To determine if this 
disruption of mitochondrial membrane potential requires de novo protein 
synthesis, cultures were switched to GM or DM supplemented with 
cycloheximide (CHX) sufficient to inhibit new protein synthesis (data not shown).  
The inclusion of CHX was sufficient to prevent the disruption in mitochondrial 
membrane potential (Fig. 2.1B). hjjhgjhgljhhghhhhsgghghgdfshdgfshdgfskdhgfskj 
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Figure 2.1 Culture in differentiation medium induces the 
mitochondrial release of cytochrome C and disruption of 
mitochondrial membrane. Equal cell numbers were plated and the next 
day cultured in DM for the indicated time in (A) or 3 h in (B). In (A), the 
mitochondrial release of cytochrome C was visualized by immunostaining 
for cytochrome C as described in Materials and methods. In (B), the 
disruption of mitochondrial membrane potential was determined in the 
presence or absence of cycloheximide (CHX) by mitocapture detection kit 
according to the manufacturer’s instructions. Error bars represent the 
standard deviation of the mean from three values from two independent 
experiments. 
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Inhibition of elevated PUMA levels blocks the release of cytochrome C and 
apoptosis  
The pro-apoptotic members of the Bcl2 family are regulated by increased 
expression and/or sub-cellular redistribution to the mitochondria (22-24). Since 
the release of cytochrome C and apoptosis relies on new protein synthesis, and 
because our lab previously focused on discerning which of the pro-apoptotic Bcl2 
family members were regulated at the level of expression, we found that PUMA 
is the only member of the Bcl2 family whose expression is increased both at the 
level of mRNA and protein in 23A2 cells as a consequence of culture in DM. We 
therefore focused our attention on PUMA. In order to determine if this increase in 
expression of PUMA is required for the release of cytochrome C and apoptosis, 
we utilized RNAi.  Recombinant lentiviruses were produced by co-transfection of 
293-T cells with the murine PUMA-specific shRNA expressing lentiviral vector, 
pLKO.1-PUMA shRNA (or control vector pLKO.1 puro), pCMV-VSV-G and pHR 
CMV-dR8.2 plasmids.  Transduced 23A2 myoblasts were then selected in 
puromycin.  PUMA expression in untreated parental 23A2 myoblasts (P), a 
vector alone-transduced 23A2 myoblast clone (C) and PUMA shRNA- 
transduced myoblast clones (23A2:shPUMA clones), each cultured in DM for two 
hours, was monitored by Western blot analysis (Fig. 2.2A) and RT-qPCR (Fig. 
2.2B).  Clones 1 and 5 displayed reduced levels of PUMA protein and mRNA and 
were analyzed further.  Clones 1 and 5, when compared to parental and vector 
control were each found to be repressed in the release of mitochondrial 
cytochrome C (Fig. 2.3A) and apoptosis (Fig. 2.3B) after culture in DM. 
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Figure 2.2 Lentiviral-mediated Puma suppression in skeletal 
myoblasts For stable and specific silencing of PUMA , a shRNA 
against PUMA RNA was used to induce silencing. Transduced cells 
were grown and analyzed. Equal cell numbers were plated and the 
next day cultured in fresh GM or DM.  In (A), myoblasts were 
cultured in DM for 2 hours prior to analysis of Puma protein by 
Western analysis as described in Fig. 2.  In (B), myoblasts were 
cultured in fresh GM or DM for 2 hours prior to analysis of Puma 
mRNA levels by RT-qPCR.  Fold increase is relative to the result 
obtained in GM. Shown is an average of 3 experiments (mean +/- 
SEM). 
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B) 
Figure 2.3 Lentiviral-mediated Puma suppression inhibits 
apoptosis and blocks cytochrome C release in skeletal myoblasts. 
In (A), myoblasts, 23A2 control and silenced clones for PUMA 
expression were cultured in fresh GM or DM for 3 hours prior to 
analysis of cytosolic cytochrome C as described in material and 
methods.  In (B), myoblasts and silenced clones were cultured for six 
hours prior to the determination of DNA fragmentation using the Cell 
Death Detection ELISA Plus kit from Roche. Shown is an average of 3 
experiments (mean +/- SEM). 
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Inhibition of elevated PUMA levels allows skeletal myoblast differentiation     
 
 Apoptosis and differentiation of skeletal myoblasts are mutually exclusive 
events. To elucidate the effect of PUMA suppression and inhibition of caspase 9 
activity on differentiation, we used a pharmacological inhibitor against caspase 9 
activity and PUMA suppressed clones.  Using this approach we showed that 
either abrogation of caspase 9 activity or silencing of PUMA expression did not 
affect the ability of myoblasts to undergo differentiation as monitored by the 
expression of myosin heavy chain (Fig. 2.4A and B).  Finally, the fact that the 
same percentage of cells stain positive for MHC in both the presence and 
absence of the caspase 9 inhibitor LEHD-fmk, and in both clones silenced and 
not silenced for PUMA expression, indicates that the myoblasts rescued from 
apoptosis can indeed differentiate.  If they could not differentiate, one would 
expect that the percentage of cells staining positive for MHC would be reduced in 
the presence of LEHD-fmk and in the clones silenced for PUMA expression.  
Similarly, since equal protein is loaded, one would expect a reduction in the 
amount of MHC detected by Western analysis in the presence of LEHD-fmk, and 
in the clones silenced for PUMA expression, if the cells rescued from apoptosis 
could not differentiate. 
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Figure 2.4 PUMA silencing or caspase 9 inhibition does not 
prevent  myogenesis .  Equal cell numbers were plated and the next 
day cultured in DM for 18 hours in the presence or absence of LEHD. 
In (A) Western blot analysis of 23A2 cell, control, silenced clones for 
PUMA using anti-MHC and anti-actin (control) antibodies. In (B) the 
percent of cells expressing MHC was assessed by immunostaining 
using anti-MHC and Texas Red conjugated anti-mouse IgG 
(Invitrogen). 10 different field of 100 cells were analyzed by two 
independent investigators. Error bars represent the standard deviation 
of the mean from three values from two independent experiments.         
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Increased expression of PUMA in 23A2 cells as a consequence of culture in 
DM is p53-independent 
Since increased expression of PUMA was originally observed in response to 
activation of the transcription factor p53 (25-27), we used pifithrin, a selective 
pharmacological inhibitor of p53 (42), to examine a potential role for p53 in the 
induction of PUMA as a consequence of culture in DM.  A role for p53 in the 
differentiation of skeletal myoblasts is well established (16, 43) so we first 
assessed the effect of pifithrin on differentiation as monitored by the expression 
of myogenin.  As predicted, pifithrin inhibited the expression of myogenin mRNA 
and protein as a consequence of culture in DM (Fig. 2.5A,B).  Pifithrin, however, 
had no detectable effect on the increased expression of PUMA mRNA or protein 
(Fig. 2.6 A,B) or the release of cytochrome C (Fig. 2.7A).  Finally, Pifithrin had no 
detectable effect on the apoptosis of skeletal myoblasts as monitored by DNA 
fragmentation (Fig. 2.7B).  This is consistent with previous reports employing 
dominant negative mutants of p53 as well as p53-/- cells which indicate that p53 
is not involved in the apoptosis of skeletal myoblasts as a consequence of culture 
in DM (16). 
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A) 
B) 
Figure 2.5  Pifithrin, a pharmacological inhibitor of P53 activity 
prevents differentiation of skeletal myoblasts as a consequence of 
culture in DM Equal cell numbers were plated and the next day 
cultured in fresh GM or DM for 18 h with or without the p53 inhibitor 
Pifithrin as indicated.  In (A), quantitative RT-PCR was performed using 
the Quantitect SyBr Green PCR kit (Quiagen) as described in  Material 
and Methods. Fold increase is relative to results obtained in GM. 
Shown is an average of 3 experiments (mean ± SEM).  In (B), whole 
cell extracts were prepared 100 g of total protein was separated by 
SDS-PAGE. Western analysis was performed using  anti-myogenin or 
anti-actin (load control). Shown are results from one experiment that 
are representative of three independent experiments. 
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A) 
B) 
Figure 2.6  Inhibition of p53 activity by pifithrin does not prevent the 
increase in  expression of PUMA mRNA and  protein as a consequence 
of culture in DM  Equal cell numbers were plated and the next day cultured 
in fresh GM or DM for 3 h with or without the p53 inhibitor Pifithrin as 
indicated.  In (A), quantitative RT-PCR was performed using the Quantitect 
SyBr Green PCR kit (Quiagen) as described in Material and Methods. Fold 
increase is relative to results obtained in GM. Shown is an average of 3 
experiments (mean ± SEM).  In (B) whole cell extracts were prepared 70 (g 
of total protein was separated by SDS-PAGE. Western analysis was 
performed using anti-PUMA antibody or anti-actin (load control). Shown are 
results from one experiment that are representative of three independent 
experiments. Error bars represent mean + SEM. 
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Figure 2.7 Inhibition of p53 activity does not affect the release of 
cytochrome C and apoptosis in 23A2 cells as a consequence of culture in 
DM Equal cell numbers were plated and the next day cultured in DM in the 
presence or absence of the inhibitor for the indicated time: 3 hrs in (A) and 6 hrs 
in (B). In (A), cytochrome C release was measured in the S100 fraction using 
Quantikine M cytochrome C ELISA kit from R&D. S100 fraction purity was det 
ermined by Western blot analysis using mitochondrial cytochrome C oxidase as 
described in Material and Methods. In (B), myoblasts were cultured in DM in the 
presence or absence of the inhibitor 6 hours prior to the determination of DNA 
fragmentation using the Cell Death Detection ELISA Plus kit from Roche. This is 
an average of three independent experiments (mean ± SEM). 
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Increased expression of PUMA, mitochondrial release of cytochrome C and 
apoptosis are induced by activation of MyoD  
 Others in our laboratory have previously shown a correlation between 
MyoD expression levels and apoptosis in 23A2 cells.  Myoblasts expressing 
oncogenic Ras were reported to have decreased apoptosis, which correlated 
with decreased levels of MyoD expression (35). This finding prompted us to 
hypothesize that MyoD activation might be sufficient to induce the expression of 
PUMA, cytochrome C release and apoptosis.  To test this hypothesis, we 
examined the ability of 10T1/2 fibroblasts stably expressing a conditionally active 
estrogen-receptor:MyoD fusion protein (ER:MyoD:10T1/2)(44) to undergo 
apoptosis in response to estrogen.  Since the estrogen receptor is not expressed 
in these cells, ER:MyoD is the only estradiol target (data not shown). Treatment 
of  ER:MyoD:10T1/2 cells with 1 M of estradiol resulted in estradiol-dependent 
activation of MyoD which was verified by immunoblot analysis of myogenin and 
this activation of MyoD was sufficient to induce differentiation comparable to that 
observed in 23A2 myoblasts (Fig. 2.8A). Comparison of estradiol treated and not 
treated ER:MyoD:10T1/2 cells indicates that this MyoD activation is also 
sufficient to induce apoptosis (Fig. 2.8B) and the increased expression of PUMA 
(Fig. 2.9A & B). Finally, estradiol treatment of ER:MyoD 10T1/2 cells, induced the 
increased expression of PUMA (Fig. 2.9A &B) but not 10T1/2 fibroblasts (Fig. 
2.9C). 
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Figure 2.8 10T1/2 fibroblast cells stably expressing ER:MyoD 
fusion protein undergo apoptosis in response to estradiol 
Equal cell numbers were plated and the next day cultured in fresh 
GM or DM with or without 1M estradiol for 4 hours. In (A), 
Western blot analysis using ant-myogenin antibody (BD 
Bioscience) to confirm activation of MyoD. In (B) equal 23A2 cell 
numbers were plated. The next day, 23A2 cells  were treated with 
one M estradiol in GM. 23A2 cells then were switched to DM as 
indicated for six hours prior to the determination of DNA 
fragmentation using the Cell Death Detection ELISA Plus kit 
(Roche) according to the manufacturer’s protocol. This result is an 
average of three independent experiments (mean ± SEM). 
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A) 
Figure 2.9 Increased level of PUMA as a consequence of 
activation of ER:MyoD in 10T1/2 fibroblasts Equal cell numbers 
were plated and the next day cultured in fresh GM or DM with or 
without 1M estradiol for 4 hours. In (A), quantitative RT-PCR was 
performed as described in Materials and methods. Fold increase in 
DM is relative to results obtained in GM.  Shown is an average of 3 
experiments (mean +/- SEM).  In (C), whole cell extracts were 
prepared after culture in DM for 4 hrs and 100 g of total protein was 
separated by SDS-PAGE.  Western analysis was performed using 
anti-Puma (Abcam) or anti-actin (load control). In (D), 10T1/2 treated 
or untreated with estrogen for 3 hours. This is an average of three 
independent experiments (mean ± SEM). 
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DISCUSSION 
 It is well established that differentiation and apoptosis are coordinately 
regulated   in many systems which can be broadly divided into two groups.  In 
some systems, apoptosis contributes to the differentiation process while in others 
apoptosis serves the purpose of eliminating excess cells (45, 46).  The skeletal 
myoblast model system is a member of the latter group (46). Elucidating the 
molecules that mediate the apoptotic process in skeletal myoblasts has revealed 
a role for caspase 3 and the TRAIL/DR5/FADD/caspase 8/tBid pathway (2, 17) 
while expression of Bcl2 confers resistance (47). We report herein the novel 
observation that mitochondrial cytochrome C is released into the cytosol upon 
removal of serum and plays a role in the apoptosis associated with skeletal 
myoblast differentiation.  Further, we report that the pro-apoptotic Bcl2-family 
member PUMA contributes to this release of cytochrome C and the ensuing 
apoptosis.  While the involvement of  PUMA in the release of mitochondrial 
cytochrome C has been established previously (26), this is the first report to 
document a role for the increased expression of PUMA in the release of 
mitochondrial cytochrome C and the ensuing apoptosis of skeletal myoblasts as 
a consequence of culture in differentiation media. Additionally, we have also 
shown that PUMA is not required for skeletal myoblast differentiation. 
 
PUMA was originally identified through global profiling as a p53-inducible 
gene and through a yeast two-hybrid screen as a Bcl2 interacting protein (25-27).  
We have used the selective p53 pharmacological inhibitor pifithrin to rule out a 
role for p53 in the induction of PUMA, the mitochondrial release of cytochrome C 
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and apoptosis in this system. These findings are in agreement with previous 
reports indicating that the apoptosis associated with skeletal myoblast 
differentiation as a consequence of culture in DM is p53-independent (16).  
PUMA is also a transcriptional target of the p53 family member p73.  The 
regulation of p73 is complex in that it is transcribed from two promoters, one 
permitting the expression of a transactivation competent (TA) protein and the 
other permitting the expression of a dominant negative (DN) protein (48).  As a 
consequence of alternative splicing, each of these can be expressed as seven 
isoforms (αβ ) with both overlapping and distinct functions.  PUMA is 
among the transcriptional targets shared by TAp73 and p53 in that ectopically 
expressed TAp73 ,  and  isoforms can increase the expression of PUMA and 
induce apoptosis in p53-null Saos cells (49).  Recently, a role for p73 has been 
investigated in both the differentiation and the apoptosis of C2C12 skeletal 
myoblasts (50, 51). In C2C12 myoblasts, expression levels of TAp73 are rapidly 
decreased within one hour of culture in DM while expression levels of both 
TAp73 and DNp73 are simultaneously and similarly modestly increased with 
culture in DM (50).  Forced expression of either isoform inhibited the 
differentiation of C2C12 myoblasts by roughly 50% suggesting that the timing of 
their expression is critical (50, 51).  Further, a decrease in the apoptosis of 
C2C12 myoblasts was observed when TAp73
in the apoptosis of C2C12 myoblasts was observed when DNp73 was silenced.  
PUMA levels, however, were not assessed (50).  We have detected an increase 
in PUMA expression as a consequence of culturing C2C12 myoblasts in DM (A. 
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Shaltouki, unpublished).  We speculate, however, that the simultaneous and 
similar increase of both TAp73  would balance their opposing 
effects on apoptosis.  Thus, while direct studies on p73 need to be performed, we 
suggest that p73 does not play a role in the increased expression of PUMA in 
skeletal myoblasts cultured in DM.  
 
  p53/p73 independent increased expression of PUMA has also been 
reported.  Specifically, glucocorticoid treatment increases PUMA expression and 
apoptosis in primary thymocytes and serum deprivation increases PUMA 
expression and apoptosis in several tumor cell lines (27).  The increase in PUMA 
expression in tumor cells in response to serum deprivation can be reversed by 
serum or specific growth factors and this reversal is prevented by inhibition of 
PI3-kinase (27).  In vivo, myoblasts are maintained in a proliferative and 
undifferentiated state by certain mitogens.  Differentiation is induced in response 
to decreasing gradients of these mitogens when myoblasts have appropriately 
migrated.  To mimic this, the in vitro differentiation of skeletal myoblasts is 
initiated by serum deprivation (52). Thus, skeletal myoblasts are a non-
transformed cell type in which serum deprivation as a consequence of culture in 
differentiation media correlates with increased expression of PUMA and 
apoptosis.  While we report herein that p53 does not appear to play a role in the 
increased expression of PUMA in skeletal myoblasts, we have previously 
reported that PI3-kinase activity decreases during the time period in which PUMA 
induction is observed (18). Further, PI3K/Akt signaling does play a role in 
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myoblast survival during differentiation (53, 54).  Decreased signaling through the 
PI3-kinase pathway allows nuclear localization of the FOXO3a transcription 
factor (55).  Thus, the PI3-kinase/FOXO pathway may be responsible for the 
increased PUMA expression in skeletal myoblasts.  However, this pathway is 
also responsible for increased expression of TRAIL and the pro-apoptotic Bcl2 
family member Bim (56, 57) in other systems and the expression level of neither 
of these proteins is increased as a consequence of culture in differentiation 
media ((17) and herein).  Interestingly, 10T1/2 fibroblasts, from which 23A2 
myoblasts are derived (39), do not undergo apoptosis in response to culture in 
differentiation media.  Further, when cultured in differentiation media, PI3-kinase 
activity decreases similarly in 10T1/2 fibroblasts and skeletal myoblasts (18) and 
C.M. Weyman, unpublished), yet PUMA induction in these fibroblasts is less than 
that observed in the skeletal myoblasts (A. Shaltouki, unpublished).  Thus, we 
believe that the PI3-kinase/FOXO3a pathway cannot completely explain the 
increased PUMA expression in skeletal myoblasts and future experiments are 
focused on determining the mechanism responsible for this increase.  
 
The irreversible nature of the apoptotic process necessitates that induction 
of such is tightly controlled and often requires the engagement of multiple pro-
apoptotic molecules.  For instance, increased expression of Hrk and Bim are 
required for neuronal apoptosis while many p53-regulated proteins such Fas, 
DR5, FLIP, Noxa, PUMA, Bax and Bad are associated with apoptosis in 
response to DNA damage (24, 58).  Further, increased expression of PUMA in 
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response to DNA damage in fibroblasts induces quiescence rather than 
apoptosis.  Speculation as to why thymocytes undergo apoptosis while 
fibroblasts become quiescent is the need for cooperation between PUMA and 
other pro-apoptotic molecules (24).  Recently, both PUMA and Bim have been 
shown to contribute to lymphocyte development and to the death of activated T-
cells (59, 60).  While herein we report that the skeletal myoblast apoptosis as a 
consequence of culture in differentiation media requires increased expression of 
PUMA, we have previously reported that this apoptotic process also requires 
signaling through the TRAIL/DR5/FADD/caspase8 cleavage of Bid pathway.  As 
is the case with some of the myoblasts in which PUMA has been silenced, some 
of the myoblasts expressing dominant negative mutants of FADD or DR5 will 
eventually undergo apoptosis (A. Shaltouki and J. O’Flaherty, unpublished).  
Thus, cooperation between PUMA and other pro-apoptotic molecules such as t-
Bid is required for the efficient apoptosis that occurs in some skeletal myoblasts 
as a consequence of culture in differentiation media.  Similarly, some of the 
myoblasts treated with the caspase 9 inhibitor will eventually undergo apoptosis 
(A. Shaltouki unpublished) suggesting a role for the permeabilization of the 
mitochondria and the ensuing release of factors capable of mediating caspase 
independent apoptosis.  However, this delay in the apoptotic process caused by 
inhibiting caspase 9 or by preventing the elevation of PUMA is sufficient to 
reduce the number of apoptotic myoblasts.  Further, those rescued are 
competent for differentiation.  These findings could be useful in efforts to treat 
disease states associated with muscle degeneration and to the effectiveness of 
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any treatment utilizing skeletal myoblast transfer. Thus, it is noteworthy that 
silencing of PUMA does not inhibit skeletal myoblast differentiation.    
 
While our studies performed on cultured myoblasts clearly demonstrate a 
role for PUMA in the apoptosis associated with skeletal myoblast differentiation, 
PUMA -/- mice develop normally with no obvious muscle related phenotype (31).  
A defective apoptotic phenotype in thymocytes and the developing nervous 
system of PUMA -/- mice is, however, observed in response to DNA damaging 
agents such as ionizing radiation.  Further, a defective apoptotic phenotype can 
be detected in thymocytes derived from PUMA -/- mice in response to 
glucocorticoid, and in myeloid progenitors in response to Myc activation and IL-6 
deprivation (31).  Thus, although PUMA appears to play no role in the normal 
development of hematopoietic cells, PUMA clearly contributes to cell death in 
response to certain stress conditions.  We, therefore, speculate that lack of a 
developmental muscle phenotype could indicate either that this pathway has no 
role during developmental myogenesis or that compensatory signaling negates 
detection of such a role.  Further, a reduced apoptotic phenotype in PUMA -/- 
skeletal myoblasts might only be observed in response to specific stimuli such as 
conditions that lead to muscle wasting or regeneration, or in the context of 
myoblast transplantation (4, 61, 62).  Finally, research on the molecules 
controlling the apoptotic process in human muscle has necessarily lagged behind 
studies performed in culture or in mice.  These studies have suggested a role for 
caspase 3 (12) (63-65).  The results presented herein suggest that assessing the 
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expression of PUMA, possibly as a molecule functioning prior to caspase 3 
activation, is warranted.  These future studies, combined with further analysis to 
understand the molecular mechanisms mediating the increased level of PUMA 
as a consequence of culture in differentiation media, might identify additional 
therapeutic targets for manipulation relevant to the use of myoblast transfer as a 
therapeutic approach or to modify skeletal myoblast apoptosis relevant to the 
amelioration of disease states with associated muscle degeneration. 
 
We also report here a pro-apoptotic role for the muscle regulatory 
transcription factor MyoD. Our previous report suggested that the survival of Ras 
expressing myoblasts correlates with decreased levels of MyoD expression (35) 
23A2 myoblasts are derived from 10T1/2 fibroblasts.  23A2 myoblasts express 
MyoD while 10T1/2 fibroblasts do not (39).  23A2 myoblasts undergo apoptosis 
in response to culture in DM while 10T1/2 fibroblasts do not (2). Increased 
expression of pro-apoptotic molecules by other transcription factors, notably p53 
(23, 66)  has been documented. p53 has the dual capacity to induce either 
growth arrest or apoptosis (67), while MyoD has the capacity to induce growth 
arrest and differentiation or apoptosis.  p53, however, is ubiquitously expressed 
and responsive to DNA damage (67) while MyoD expression is restricted to 
skeletal muscle and responsive to differentiation cues (68).  To our knowledge, 
the only other report of basic helix-loop-helix (bHLH) transcription factors shown 
to play a role in apoptosis are the Daughterless-like (HLH-2) and Achaete-scute-
like (HLH-3) bHLH transcription factors responsible for inducing apoptosis during 
neuronal development in C.elegans (69). Here, we demonstrated that estradiol-
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induced activation of MyoD:ER fusion protein in DM was sufficient to result in  the 
increased expression of PUMA and apoptosis. In light of this information, the 
ability of MyoD to induce growth arrest and differentiation or apoptosis is redolent 
of p53 function. These data were consistent with other published reports 
suggesting that MyoD may play a role in apoptosis (70).  
 
CONCLUSION 
Mitochondrial release of cytochrome C, activation of caspase 9 and the apoptosis 
associated with skeletal myoblast differentiation require de novo protein 
synthesis.  PUMA was identified in a search for increased expression of pro-
apoptotic Bcl2 family members as a consequence of culturing skeletal myoblasts 
in differentiation media.  Stable RNAi mediated silencing of this increase in 
PUMA expression decreases the mitochondrial release of cytochrome C and the 
ensuing apoptosis.  Myoblasts rescued from apoptosis by either inhibition of 
elevated caspase 9 activity or silencing of PUMA are competent for 
differentiation.  As p53 does not play a role in this apoptotic process, experiments 
are underway to understand the regulation of PUMA in this system. Finally, we  
showed that activation of MyoD is sufficient to induce apoptosis through the 
increased expression of PUMA. 
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CHAPTER III 
 
TRANSLATIONAL REGULATION OF THE PRO-APOPTOTIC BCL2 FAMILY 
 
 MEMBER PUMA  
 
ABSTRACT 
 
We have previously reported that culture of 23A2 myoblasts in differentiation 
media (DM) induces an increase in both the mRNA and protein levels of the pro-
apoptotic Bcl2 family member PUMA and that PUMA is critical for the apoptotic 
process that occurs in a subset of these myoblasts.  Herein, we report a novel 
translational regulation mechanism of PUMA.  Specifically, we have determined 
that culturing of myoblasts in DM with actinomyocin D is sufficient to block the 
increase in PUMA mRNA levels, but does not prevent the increase in PUMA 
protein levels.  Further, metabolic labeling of newly synthesized proteins in 
myoblasts cultured in either growth media (GM) or DM supplemented with 
actinomycin D followed by immunoprecipitation of PUMA has allowed us to 
conclude that this increase in PUMA protein is a consequence of increased 
translation. Polyribosome analysis of PUMA mRNA indicated that translational 
regulation most probably occurs at the initiation step.  We have also found that 
the increase in PUMA protein levels occurs under conditions of eIF2-
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alpha phosphorylation and subsequent global decrease in total protein synthesis.  
Analysis of the 5’ UTR of PUMA mRNA by Mfold program predicts stable 
secondary structures incompatible with efficient ribosome scanning. Further, we 
have determined that impairment of cap-dependent translation in vitro and in vivo 
did not affect the translation of PUMA mRNA. Finally, we have generated data 
indicating that the increased translation of PUMA in DM is mediated by an 
internal ribosome entry site (IRES). Using mono- and bi-cistronic reporters, we 
have identified a fragment of PUMA mRNA that allows for cap-independent 
translation in vitro and in vivo in response to culture in DM. This fragment 
encompasses regions upstream and downstream of the initiation AUG codon 
Thus, our data indicate that increased expression of PUMA in skeletal myoblasts 
relies on IRES-meditated translation. 
 
INTRODUCTION 
Translation Initiation (cap dependent translation)  
The regulation of global translation is an important process that allows a 
cell to respond rapidly in response to environmental cues (1). Regulation of 
protein synthesis can occur at many steps during the process but in many cases 
the initiation step is subject to regulation. Initiation begins with binding of the 40S 
ribosomal subunit to the initiator Met-tRNA-Met in a ternary complex with 
eukaryotic initiation factor 2α (eIF2α) and its bound GTP. Initiation of protein 
synthesis requires recruitment of this small ribosomal subunit to the mRNA (2, 3). 
This recruitment is mediated by a cap-binding protein complex known as 
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eukaryotic initiation factor-4F (elF4F). The elF4F complex is composed of 3 
subunits. EIF4E(4),  the smallest subunit of the elF4F complex, is a cap-binding 
protein which recognizes the cap structures (m7GpppN) at the 5-end of the 
mRNA. elF4A, another subunit of the elF4F complex, has RNA helicase activity 
(5), and elF4G (6), the third subunit of elF4F complex, acts as a scaffold protein 
connecting the small ribosomal subunit and the mRNA through elF3 (7-10). Once 
the ribosome is recruited to the 5 end of mRNA through its interaction with 
elF4F, its binding to the mRNA is facilitated through the unwinding of mRNA 
secondary structures in the 5 untranslated region (5UTR). This unwinding is 
mediated by eIF4A and eIF4B (11).  Initiation of translation is then achieved by a 
scanning process through which the ribosome and its associated factors begin to 
scan the mRNA in a 5 to 3 direction. After recognition of an initiation codon with 
the appropriate sequence context by the anticodon of Met-tRNAMet, hydrolysis of 
the GTP bound to eIF2 is facilitated by eIF5, an GTPase activating protein.  eIF1  
then releases small ribosomal subunit bound initiation factors which are recycled 
for another round of translation initiation (12). Joining of the large ribosomal 
subunit 60s to the initiation complex is stimulated by eIF5B (13) and hydrolysis of 
a second molecule of GTP, leads to formation of the 80s initiation complex (14, 
15). 
 
4E-BP 
  Since the formation of the elF4F complex is required for initiation, the 
regulation of translation initiation can be achieved by controlling the availability of 
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elF4E. 4E-binding proteins (4E-BPs) are a family of translational repressors that 
compete with eIF4G for binding to elF4E. Thus, binding of 4E-BPs to eIF4E 
inhibits cap-dependent translation (9, 16). Assembly of the eIF4F complex is 
regulated by the phosphorylation status of 4E-BP. While hypophosphorylated 4E-
BP binds to eIF4E with high affinity, sequestering it from incorporation into the 
eIF4 complex, hyperphosphorylation of 4E-BP releases eIF4E (9, 16-19)   
Although inhibition of translation initiation by 4E-BP is reversible, the release of 
eIF4E from 4E-BP requires phosphorylation of a combination of multiple residues 
in a hierarchical manner (20) (Fig. 3.1). 
 
Regulation of translation by insulin and other growth factors has been 
reported (9, 21).  It has been shown that both serum and growth factors affect the 
phosphorylation status of 4E-BPs. Hyperphosphorylation of 4E-BP upon serum 
stimulation allows cap-dependent translation (16, 22-26). Recent studies have 
identified PI3K (phosphoinositide3-OH kinase) ,  its downstream effector Akt, and 
the AKT substrate mTOR (mammalian target of rapamycin),  as the intracellular 
signaling pathway responsible for the increase in phosphorylation of 4E-BP in 
response to serum stimulation (4, 18, 27). Wortamine is a selective 
pharmacological inhibitor of PI3K while rapamycin is a selective pharmacological 
inhibitor of mTOR. It has been reported that 4E-BP phophorylation in response to 
serum is wortaminin and rapamycin sensitive, suggesting that signaling by PI3K 
through Akt to mTOR is responsible for 4E-BP phosphorylation (18, 27-29). The 
involvement of PI3K/Akt signaling pathway in regulating myogenesis is well 
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established.  Differentiation of cultured myoblasts in response to serum 
depravation is believed to be mediated through autocrine/paracrine actions of 
IGFII (30-32). Our lab previously reported that, in response to culture in DM, 
signaling by PI3K to Akt initially decreases and then returns to levels comparable 
to that observed in GM (33).   
 
TOR was originally identified through a genetic screen in S. cerevisiae to 
be responsible for rapamycin toxicity (34).  mTOR and its yeast homolog belong 
to a larger protein family known as PIKK (phosphoinositide kinase-related kinase) 
which includes other members such as ATM (ataxia telangiectasia mutated), 
ATR (ataxia telangiectasia and Rad3) and DNA-PKc (DNA-activated protein 
kinase catalytic subunit) (35-41). It has been suggested that in yeast, TOR’s 
control of cell proliferation is achieved through a translational regulation 
mechanism (22, 42). Regulation of translation initiation by mTOR and its yeast 
homologue is mediated by its ability to phosphorylate 4E-BP or S6K1. While the 
phosphorylation of 4E-BP contributes to cap-dependent translation initiation, 
S6K1 phosphorylation regulates oligopyrimidine tract-dependent translation 
initiation. 
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Figure 3.1 Phosphorylation of 4E-BP allows translation.  
Hypophosphorylated 4E-BP binds to eIF4E with high affinity and sequesters it 
from entering into the preinitiation complex, while phosphorylation of 4E-BP in 
response to growth factors or insulin releases eIF4E and allows translation. 
 
4E-BP
P
p
p
e
IF
3
e
IF4A
e
IF
4
G
40S
PA
BP
4E
CAP
4E CAP
4E-BP
3’
p
No Translation
Translation
Phosphorylation of 4E-BP 
43S preinitiation complex
 
  69 
eIF2α  
eIF2α is a eukaryotic translational initiation factor that is involved in 
formation of the 43S preinitiation complex (Fig. 3.2). Binding of eIF2α with GTP 
and Met-tRNAMet forms a ternary complex which mediates the recruitment of Met-
tRNAMet to the small ribosomal subunit, forming the 43S preinitiation complex. An 
alternative mechanism for the regulation of global translation depends on the 
availability of this translational ternary complex which only forms when eIF2α is in 
its GTP- bound state. Reinitiation of translation requires recycling of eIF2α -GDP 
which is produced at the end of each initiation step to eIF2α -GTP is catalyzed by 
eIF2B, a guanine nucleotide exchange factor (Fig 3.2). Phosphorylation of the 
alpha subunit of eIF2α on Ser-51, in response to different physiological stimuli 
inhibits elF2B activity. Thus,  phosphorylation of the α subunit of eIF2-GDP 
prevents GDP-GTP exchange of nonphosphorylated eIF2-GDP therefore 
impairing ternary complex formation  (43, 44). Currently, four eIF2α kinases are 
known : the double-stranded RNA-dependent eIF2 kinase (PKR) (45, 46), the 
eIF2 like kinase-like endoplasmic reticulum kinase (PERK) (47), heme regulated 
eIF2 kinase (HRI) (48) and the mammalian orthologue of the yeast GCN2 protein 
kinase (mGCN2), only GCN2 activation has been linked to culture in the absence 
of serum (49).   
 
dsRNA-activated protein kinase (PKR) is an interferon inducible serine-
threonine kinase which was originally linked to the antiviral response. Recently,  
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Figure 3.2 Phosphorylation of of serine 51 on the α subunit of 
eIF2 by eIF2 specific stress kinases in response to different 
stimuli makes it a competitive inhibitor of eIF2B preventing the 
exchange of GDP to GTP and inhibit translation initiation.  
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caspase-dependent activation of PKR has been reported. In this cleavage-
induced mode of activation, cleavage of PKR at an Asp residue frees the 
catalytic domain from the control of the regulatory domain resulting in a free 
kinase domain which is constitutively active (50).  PKR-mediated phosphorylation 
of eIF2α in a caspase-dependent manner lends support to previous published 
data reporting inhibition of total protein synthesis during apoptosis (51). PERK is 
an ER resident kinase that is activated by stimuli triggering unfolded protein 
response within ER (52-58). HRI is a heme-regulated translational inihibitor and 
plays a role in inhibition of total protein synthesis during heme deficiency (59).  
 
Internal Ribosome Entry Site (IRES) 
Initiation of translation of eukaryotic mRNAs results in the formation of the 
80s ribosome-initiation complex at a start codon within the mRNA. For the 
majority of cellular mRNAs, initiation is achieved by a scanning mechanism, 
which involves  ribosomal loading on the mRNA through recognition of the 5 cap 
structure, a 7-methyl-guanylic acid residue, by a cap-binding complex known as 
eIF4F(7, 60). Recently, an alternative mechanism has been identified for 
translation initiation which is independent of cap structure.  Some viral and 
eukaryotic cellular mRNAs contain IRES (internal ribosomal entry sites) in their 5 
untranslated region (5 UTR) and translation of these mRNAs can be initiated by 
direct recruitment of the 43S ribosome-preinitiation complex to this cis-element 
which is generally in close proximity to the initiation codon (61-63).   
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IRES elements were originally identified in viral mRNAs and it was shown that a 
variety of viral mRNAs are capable of internal initiation. Recent findings suggest 
however, that many cellular mRNAs with  diverse cellular functions use IRES-
mediated internal initiation to maintain their protein synthesis under stress 
conditions where the cap function is compromised (64-67).  For instance, it was 
shown that during apoptosis, cleavage or alteration of many initiation factors 
results in a decrease in cap-dependent translation. However,  synthesis of 
proteins such as Apaf1,  Xiaps, and c-myc are maintained (68, 69). Analysis of 
IRES elements within the 5UTR of several viral mRNAs has revealed an RNA 
fold profile displaying several structural domains and short motifs important for 
internal ribosomal entry. In viruses, these structural features are reported to be 
conserved among closely related species. In contrast to viral IRESs,  
conservation of secondary structures is not observed among  IRESs of cellular 
mRNAs (70-73). 
 
 The requirement for canonical initiation factors to mediate internal 
initiation varies among different IRES-containing mRNAs.  The requirement of 
eIF4G and eIF4A  for picornaviral IRES-mediated translation has been 
established (74).  Recent discoveries suggest that the efficiency of some IRES-
mediated translation for some mRNA requires transacting factors which are RNA 
binding proteins. The first example of these cellular proteins was a 57 kDa 
polypyrimidine –tract-binding protein (PTB) known previously as a splicesome 
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component. PTB was found to be essential for the IRES-dependent translation of 
EMCV and poliovirus (62, 75, 76). Several other IRES Transacting Factors 
(ITAFs) have been identified by in vitro reconstituted translation assays,  
including  LA autoantigen (77),  Poly(rC) binding protein 2 (PCBP2) (78, 79)and 
upstream of N ras (unr) (80).   
 
As it was mentioned earlier, the inhibitory effect of serum deprivation or 
apoptosis on total protein synthesis has been described. We have shown that the 
expression of PUMA is induced concurrently with apoptosis as we switch the 
culture of 23A2 cells to DM. Although transcriptional regulation of PUMA is well 
established, we noticed that enhanced PUMA expression could occur in the 
absence of newly synthesized PUMA transcript; therefore, we began to 
investigate the translational regulation of PUMA expression in response to 
culture in DM. 
  
MATERIALS AND METHODS 
Cell lines and cell culture 
23A2 murine skeletal myoblasts are derived from 5-azacytidine treatment of 
10T1/2 fibroblast (81). They were cultured on gelatin coated plates and 
maintained in growth medium consisting of basal modified Eagle’s medium 
(BME), 10% fetal bovine serum (FBS) and  1% penicillin/streptopmycin (P/S).  
 (P/S =10000 I.U./ml of penicillin and 10000 g/ml of streptomycin).  HeLa and 
293T cells were maintained in Dulbecco’s modified Eagle’s medium 
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supplemented with 10% FBS and 1% of P/S. Differentiation was induced by 
switching 23A2 cells to DM which lacks serum. Cells were maintained at 37C in 
5% CO2. Actinimycin D was purchased from Sigma and was used at final 
concentration of 5 g/ml or 10 g/ml in DMSO. Rapamycin was purchased from 
Sigma and was used at final concentration of 100ng/ml in DMSO. 
 
Statistical analysis 
Error bars in our data represent the mean + standard deviations. Statistical 
analysis was performed using a student’s t test (paired t test) and p values less 
then 0.05 were considered significant. 
  
Silencing of PUMA using siRNA   
Custom SMARTpool plus small interfering RNA (siRNA) to target mouse PUMA 
(GenBankTM accession number NM_133234) was designed and synthesized by 
Dharmacon (Lafayette,CO). siRNA  (1.5 g) was transfected into 23A2 cells in 
GM using RNAiFect  Transfection Reagent (Qiagen) as described by the 
manufacturer’s protocol.  siCONTROL Non-Targeting siRNAs  were included as 
a control. After 48 hours of transfection, cells were treated for 3 hours in DM. 
Total RNA was isolated from cells using TriZol (Invitrogen) and 0.5 g of total 
RNA was reverse-transcribed using SuperScript III RNase H reverse 
transcriptase (Invitrogen) to produce cDNA according to the manufacturer’s 
protocol. Silencing was monitored at the mRNA level by Real-time PCR. 
Quantitative Real-time PCR was performed using Opticon & QuantiTect SYBR 
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GREEN PCR Master Mix (Qiagen). Analysis of each sample was performed in 
duplicate or triplicate and normalized to actin mRNA levels.  
 
Real-time analysis 
 Total RNA was prepared using 1 mL of Trizol (Invitrogen) reagent per plate for 
lysis following the manufacturer's instructions. 500 ng of total RNA was used to 
synthesize the first cDNA strand using reverse transcriptase SuperScript III 
(Invitrogen) in a 20 l reaction. 2 µl of the synthesized cDNA was used in 
subsequent quantitative PCR analysis using SyberGreen (Invitrogen).  Primer 
pairs used for amplification of PUMA mRNA were a forward PUMA primer:  
CCTCAGCCCTCCCTGTCACCAG and a reverse PUMA primer: 
CCGCCGCTCGTACTGCGCGTTG. Briefly, 2 L of synthesized cDNA was 
mixed with 0.3 M of each PUMA primer and 10 l SYBR green reagent 
(Invitrogen) in a total of 20 L reaction. cDNA was amplified for 39 cycles at an 
annealing temperature of 55 °C. Fluorescence was detected using an Opticon 
Monitor (MJ Research).  The cycle number at which the amplification of product 
began to increase linearly (cycle threshold (Ct) value) was set manually and 
taken from the Opticon software. The fold difference between the Ct values of  
PUMA and GAPDH was determined. 
 
Western blot analysis  
The cells were washed with 1X PBS and lysed with 1X p21 lysis buffer (20 mM 
MOPS pH 7.4, 4 mM magnesium chloride, 200 mM sucrose, 0.1 mM EDTA, 
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0.001% DNase,1 M phenyl methyl sulfonyl floride, 50 g/ml each of aprotinin, 
pepstatin, and leupeptin) with 1% CHAPS. Protein concentration was determined 
using Coomassie Protein Assay Reagent (Pierce) as per manufacturer’s 
instruction and equal amounts of lysate were denatured in 5X reducing buffer 
(50% glycerol, 10% 2-β-mercaptoethanol, 10% SDS, pH 6.8). Samples were 
heated in sample buffer to 95C for 5 minutes and loaded on a 12% SDS-PAGE. 
Samples from the gel were transferred electrophoretically to a polyvinylidene 
difluoride (PVDF) membrane in transfer buffer (containing 5.8 g/L of Tris, 29 g/L 
glycine, 20% methanol, 1 g/L of SDS ) for 40 minutes at 1500 mAmp. The 
membrane was blocked with 5% milk in wash buffer (1X TBS with 1% NP-40) for 
one hour and incubated with primary antibody in wash buffer overnight at 4C. 
The following primary antibodies were used for incubation with the appropriate 
membranes at the specified dilution: anti-PUMA antibody (Abcam) at 1:1000 
dilution, anti-phospho 4E-BP antibody  and anti-4E-BP anti-body (Cell Signaling) 
at 1:1000 dilution,  anti-phospho mTOR antibody (Cell Signaling) at 1:1000 ,  
anti- anti-phospho eIF2 (Ser51) antibody (Cell Signaling) at 1:1000, anti-eIF2α 
(Cell Signaling) antibody at 1:1000, and anti-PKR  antibody 1:1000 and Anti-ß-
actin (Sigma) was used at a dilution of 1:30, 000 for one hour as the control for 
equal loading. The membrane was washed three times with wash buffer after 
incubation with the primary antibody. The membrane was then incubated with the 
appropriate horseradish peroxidase-conjugated secondary antibody (Santa Cruz)  
 diluted at 1:1000 for one hour. Prior to visualization, the membrane was washed 
again 3 times with wash buffer. SuperSignal West Pico Chemiluminescent 
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Substrate (Pierce) was incubated with the membrane for 2 minutes and 
visualization was performed using a Kodak Scientific imaging film.  
 
Immunoprecipitation of  35S-metabolically labeled PUMA 
23A2 cells were plated at equal density at 1X105 cells per 100 mm plate the night 
before. The next day, the cells were washed with cold 1X PBS (Phosphate Buffer 
Saline) and preincubated in cysteine/methionine-free PRMI media (HyClone) for 
30 minutes at 37C. 23A2 cells were then incubated with cysteine/methionine-
free medium containing 35S-methionine (0.5 mCi.ml-1 in total of 4 ml of medium) 
(MP Biomedicals Inc) with actinomycin (5 g/ml) in the presence or absence of 
10% dialyzed fetal bovine serum (HyClone). After three hours, 23A2 cells were 
washed with cold 1X PBS and then lysed by scraping in 70 l of 1X RIPA lysis 
buffer (Tris 50 mM, NaCl 150 mM, SDS 0.1 %, phenyl methyl sulfonyl floride 
1mM, EDTA 1 mM, Triton X100 0.1% and 1X protease inhibitor). 
 
  Further disruption of cells was achieved by repeated freeze-thaw 
procedures. For immunoprecipitation, 35S-labeled lysates were depleted of 
endogenous Igs by preclearing them with Protein A/G agarose beads (Santa 
Cruz) for one hour at 4C.  Precleared 35S-labeled GM or DM supernatant was 
removed after centrifugation at 2500 rpm for 30 sec at 4C. Equal aliquots of 
protein from each precleared supernatant were incubated with 10 l 
immunoprecipitation antibody (rabbit polyclonal antibody against PUMA 
(Abcam):70 l of Immunoprecipitation matrix (ExactaCruz from Santa Cruz) 
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complex overnight at 4C. Immunocomplexes were pelleted at maximum speed 
at 4C the next day and were washed four times with RIPA buffer containing 
protease inhibitors.  The final pelleted complex from each lysate was 
resuspended in 70 l of 2X reducing electrophoresis buffer (50% glycerol, 10% 2-
β-mercaptoethanol, 10% SDS ) and boiled for 3 minutes at 95C.  To elute 35S-
labeled PUMA proteins, the sample loading buffer was centrifuged at 13000 rpm 
for 1 minute. The 35S-labeled precipitated PUMA proteins was subjected to SDS-
polyacrylamide gel electrophoresis (12%). The Gel was fixed in 50% methanol, 
10% acetic acid fixation solution, soaked for 15 minutes in Amplify (Amersham 
Pharmacia Biotech), dried for 90 minutes at 65 °C, and visualized by a Typhoon 
scanner. 
  
Total protein synthesis (Metabolic labeling with 35S-methionine) 
23A2 cells were plated at equal density in 6-well plates the night before. The next 
day, cells were washed with cold 1X PBS (Phosphate Buffered Saline) and 
preincubated in cysteine/methionine-free PRMI media (MP Biomedicals) for 30 
minutes at 37C. To measure newly synthesized protein under different 
conditions, after brief amino acid starvation, 23A2 cells were incubated with 
cysteine/methionine depleted medium containing 35S-methionine (40 mCi.ml-1) 
(MP Bipmedicals) in the presence or absence of 10% dialyzed fetal bovine serum 
(HyClone). At the various time points indicated on the graph, cells were washed 
with cold 1X PBS and then lysed in 50 l of 1X p21 lysis buffer (20 mM MOPS 
pH 7.4, 4 mM magnesium chloride, 200 mM sucrose, 0.1 mM EDTA, 0.001% 
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DNase, 1M phenyl methyl sulfonyl floride, 50g/ml each of aprotinin, pepstatin, 
and leupeptin) with 1 % CHAPS. The lysates were subject to further lysing by two 
consecutive freeze-thaw procedures. Protein determination was performed using 
Coomassie Protein Assay Reagent (Pierce) as per the manufacturer’s 
instructions and equal amounts of protein from each lysates was subject to 
trichloroacetic acid (TCA) precipitation (10%). 5 l of 35S-labeled precipitated 
protein from each lysate was placed onto a 25-mm-diameter glass fiber filter 
(Fisherscientific Inc). The filters were washed three times in 5% TCA and once in 
100% ethanol, air dried and subjected to scintillation counting. 
 
Polyribosome Analysis.  
A. Sucrose gradient prepration 
Polysome buffer was made by mixing 100 mM KCL, 2.5 mM MgCl2, 10 mM 
Hepes-KOH (pH 7.4), 1 mM DTT in a 250 ml volume of DEPC-treated water. 
To make a sucrose gradient of 5-50% using a gradient maker,  6 g of sucrose 
was dissolved in 120 ml of polysome buffer (5% sucrose solution) and 60 g of 
sucrose was dissolved in 120 ml of polysome buffer (50% sucrose solution ). 60 
ml of each sucrose solution was then loaded into the gradient maker (in different 
channels of the gradient maker) to make 2 gradients. Gradient maker’s pump 
was set at 1 revolution /20sec. The gradient was collected in collection tubes with 
5% solution moving upward as the concentration of sucrose solution was 
increased. The gradient was poured at least 4 hours before use and allowed to 
equilibrate at 4C. 
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 B. Equal number of cells were plated in 15cm tissue culture dishes. The next 
day, cells were switched to fresh GM (growth media containing 10% FBS) or DM 
(differentiation media) for 3 hours. Prior to harvesting, cells were treated with 100 
g/ml of cycloheximide for 15 minutes at 37C. Cells were washed twice with 
cold 1X PBS containing cycloheximide. Cells were then scraped in cold 1X PBS 
containing cycloheximide. Harvested cells were collected by centrifugation at 
1500 xg for 10 minutes at 4C. 
 
  Pelleted cells were lysed by incubation with 500 l of lysis buffer (10 mM 
HEPES-KOH (pH 7.4), 2.5 mM MgCl2,100 mM KCL, 1 mM dithiothreitol, 0.1% 
Nonidet P-40,  RNasin (100 units/ml) and 100 g/ml cycloheximide for 15 
minutes on ice. Further lysing of cells was insured by freeze-thaw procedure. 
Lysed cells were then subject to centrifugation at 10000 xg to remove cellular 
debris and mitochondria.  Post-mitochondrial cytoplasmic extract (supernatant) 
was collected and an equal optical density unit (260A) of each cytoplasmic 
extracts from GM or DM samples was determined and layered over 5-50% 
sucrose gradient (10 mM Hepes-KOH (pH 7.4), 100 mMKcl, 2.5 mM MgCl2, 
1mMdithiothreitol) and centrifuged at 17,000 rpm for 18 hours at 4C using a 
Beckman rotor. Fractionation of gradients was performed using ISCO density 
gradient fractionator with absorbance monitor set at 260 nm. Twenty five 
fractions were collected. RNA was collected from each fraction using TriZol 
reagent (Invitrogen) per the manufacturer’s instruction. 500 ng of total RNA from 
each fraction was used in a reverse transcription reaction using reverse 
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transcriptase SuperScript III (Invitrogen). 2 l of each RT reaction was used for 
quantitative Real-time PCR analysis as described above using PUMA or GAPDH 
specific primers.  
 
Cap analog experiment  
 pBluescript vector (Invitrogen) was a generous gift from Dr. Anton Komar 
(Cleveland State University). The entire PUMA cDNA was amplified by PCR 
using primers: EcoRI forward: 
AAAAAGAATTCCCAGGAGGCGGCGGCGACACCAGC 
Sac I reverse: AAAAAGAGCTCTTACAGCGGAGGGCATCAGGCGG. The 
resulting PCR product was digested with SacI and EcoRI and was cloned  
.in pBluescript backbone vector digested with SacI/EcoRI. The final construct 
was verified by sequencing and was linearized with HindIII. The pCAT vector was 
used as a positive control since its translation is strictly cap-dependent. 100 ng of 
linearized DNA was used in an in vitro transcription reaction to produce capped 
and polyadenylated RNA using Archacap Ultra Machine Message (Promega). 
500 ng of RNA was subjected to an in vitro translation reaction in the presence or 
absence of increasing concentrations of m7G(5)ppp(5)G cap analog (Ambion) 
and 10 Ci of Trans 35S-Label Met/Cys (MP Biomedicals) . Reactions were 
resolved on a 12% SDS-PAGE . Gel was fixed in 50% methanol and 10% acetic 
acid fixation solution, soaked for 15 minutes in Amplify (Amersham Pharmacia 
Biotech), dried for 90 minutes at 65°C and visualized on a Typhoon  scanner and 
the amount of radioactivity was quantified for each band. 
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 In vitro transcription and translation 
 pGEM-CAT-fLuc was a gift from Dr Komar (Cleveland State University). Its 
construction has been described previously (82). The sequences spanning  
5UTR of PUMA ,  5UTR of PUMA + 50 nt and 5UTR of PUMA + 100 nt  past 
the initiation codon  were each amplified by PCR using PUMA cDNA (Invitrogen 
MG 67917) as a template and with the following primers: BamHI bbc3 forward: 
AAAAAGGATCCCCAGGAGGCGGCGGCGACACCAGC,  BamHI bbc3 +1 
reverse : AAAAAGGATCCACATGGCGCTCCCTGGAGCCCC,  BamHI bbc3 +54 
reverse: AAAAAGGATCCATACAGCGGAGGGCATCAGGCGG and BamHI bbc3 
+102+1 reverse:AAAAAGGATCCAGCGGGCTAGACCCTCTACGGGCTCC 
The resulting PCR fragments were digested with BamHI and were each cloned 
into a pGEM-CAT-fLuc vector at BamHI site. Constructs were verified by 
sequencing. The resulting vectors were linearized with XhoI (Invitrogen). A total 
of 1 g of each DNA construct (pGEM  bicistronic vector control, pGEM- PUMA 
5UTR , PGEM- PUMA-5UTR-(+50) and pGEM-PUMA-5UTR-(+100)) was  
linearized and transcribed in vitro using mMESSAGE mMACHINE T7 Ultra kit 
(Ambion) according to the manufacturer’s instructions. The integrity of RNA 
transcripts was verified by running them on an urea-PAGE. 2 g of each capped 
RNA was in vitro translated using nuclease-treated rabbit reticulocyte lysate 
(Promega) in the presence of 35S-methionine (10 l). The resulting radiolabeled 
protein products were resolved on a 12 % SDS-PAGE.  The gel was fixed in 50% 
methanol and10% acetic acid fixation solution, soaked for 15 min in Amplify 
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(Amersham Pharmacia Biotech), dried for 90 minutes at 65°C, and visualized on 
a Typhoon scanner. The amount of radioactivity was quantified for each band. 
 
Monocistronic contructs  
 We used the monocistronic expression vector pUHD10-3/LUC. This vector was 
a generous gift from Dr. Hatzoglou (Case Western University) and its generation 
has been described in detail (83). It was generated by cloning the chimeric LUC 
cDNA into the Xba/EcoRI site of pUDH10-3.  This vector contains a minimal 
cytomegalovirus promoter and the SV40 polyadenylation signal. To generate the 
monocistronic vector harboring the 5 UTR of PUMA with an additional 50 nt or 
100 nt past the initiation codon, we amplified PUMA cDNA by polymerase chain 
reaction using the following primer sequences: EcoRI forward: 
AAAAAGAATTCCCAGGAGGCGGCGGCGACACCAGC 
 and 
AAAAATCATGAATACAGCGGAGGGCATCAGGCGG; Pag I reverse:  
AAAAATCATGAAGCGGGCTAGACCCTCTACGGGCTCC.  A 300 or a 350-bp 
PCR product was amplified from PUMA cDNA (Invitrogen) using this approach. 
The PCR products were digested with EcoRI and BspHI and inserted into the 
EcoRI/NcoI site of the pUHD10-3/LUC. We also obtained phpUDH10-3/luc from 
Dr. Hatzoglou. The hairpin was generated as described previously (83) using 
phosphorylated primers: 5- GGAAGCTTATCGATTTCGAACCCGGGTACCG 
 AND 5- AATTCGGTACCCCGGGTTCGAAATCGATAAGCTTCCGC  
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which were annealed and inserted at a unique SacII site 70 nt downstream of the 
transcription start site. The identity of each vector was verified by sequencing.  
 
Dicistronic constructs  
To make dicistronic constructs harboring the PUMA 5 UTR and different regions 
past the initiation codon, we obtained the pRF vector from Dr. Jian-Ting Zang, 
(Indiana University). This vector is a generous gift from Dr. Stonely. It contains 
both Renilla and Firefly luciferase genes and its generation is described 
previously (68). We also obtained a dicistronic control php-RF vector from Dr. 
Jian-Ting-Zang which was made by inserting a stable hairpin upstream of the 
Renilla gene at the EcoRV site in the pRF vector using a double-stranded 
oligonucleotide with sense strand of 5-
ATCAAAAGCGCAGGTCGCGACCGCGCATGCGCGGTCGCGACCTGCGCTAA
AGAT-3 (84). We amplified the 5UTR of PUMA and 100 nucleotides past the 
initiation codon from PUMA cDNA using primers: 
EcoRI forward: AAAAAGAATTCCCAGGAGGCGGCGGCGACACCAGC 
Pag I reverse:  AAAAATCATGAAGCGGGCTAGACCCTCTACGGGCTCC 
The PCR product was digested with EcoRI and BspHI and inserted at 
EcoRI/NcoI sites in pRF and phpRF vectors. The resulting vectors were verified 
by sequencing. 
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Cell Transfections and repoter analysis 
23A2 Cells were plated at a density of 1X105 cells per plate (6 Well) in GM.  The 
next day, cells were transfected with 2 g/well of either monocistronic or 
dicistronic reporter plasmids using LipofectAMINE Plus reagent (Invitrogen) 
according to the manufacturer’s instructions. In monocistronic reporter assay, 
cells were cotransfected with 800 ng/well of pSV- β-galagtosidase expression 
vector (Promega). Hela cells were transfected with 500ng of bicistronic vector 
while 293T cells were transfected with 2ug of bicistronic plasmid using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruction. After 
incubation at 37 for 24 h, the cells were switched to fresh GM or DM for 3 hours 
(in case of 23A2 cells) and treated or untreated cells were collected for reporter 
assays. For monocistronic repoter assays, Firefly luciferase activity was 
measured using Luciferase Assay System (Promega) and was normalized to β-
galagtosidase activities as measured by the β-galagtosidase Enzyme Assay 
System (Promega). For dicistronic reporter assays, Firefly and Renilla luciferase 
activities were determined using the Dual-Luciferase Reporter Assay System 
(Promega) according to the manufacturer’s instructions 
 
Promotorless bicistronic vector. pRF vector was digested with SmaI and 
EcoRV to remove the simian virus 40 (SV40) promoter sequence and the 
chimeric intron from pRF dicistronic vector. The resulting digestion product was 
religated using T4 ligase to generate a promoterless dicistronic pRF(-p) vector. 
PUMA 5UTR and 100 nt past the initiation codon was amplified as described 
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above and the resulting PCR product was inserted into an EcoRI/NcoI site within 
the promoterless pRF to generate pR-PUMA- F(-P).  
 
RT-PCR analysis of the transfected bicistronic pRF vector harboring PUMA 
5UTR. 23A2 cells were transfected with 2 g of pRF vector containing PUMA 
5UTR in the intercistronic region using LipofectAMINE Plus reagent (Invitrogen) 
according to the manufacturer’s protocol. 24 hours after transfection, total RNA 
was isolated using TriZol (Invitrogen) reagent. 5 g of RNA was subjected to 
DNase treatment (Promega) followed by phenol/chloroform extraction. 0.5 g of 
DNase-treated RNA was used for a 20 L reverse transcription reaction in the 
presence or absence of SuperScript III reverse transcriptase (Invitrogen).  2 l of 
each RT and –RT reaction was used for PCR using the following primer set:   
  Fwd AGCAGCAAGGTGCCTCAATAG and Rev 
TGATGTCCACCTCGATATGTG   
   
 
 
 
 
 
 
 
 
 
 
 
  87 
 
RESULTS 
 
 
Increased levels of PUMA protein in the absence of increased PUMA 
message  
 
We have previously reported that an increase in PUMA mRNA (Fig 3.3A) 
and protein (Fig 3.3B) is detected in lysates from 23A2 myoblasts cultured in DM 
as compared to GM. This increased level of PUMA mRNA can be abrogated by 
prior incubation with siRNA targeting PUMA but not by prior incubation with non-
targeting control siRNA (Fig. 3.3A). However, this suppression of increased 
levels of PUMA message did not correspond to a suppression of PUMA protein 
(Fig. 3.3B).  Further, treatment with actinomycin D abrogated the increase in 
PUMA mRNA but had no effect on the increased level of PUMA protein (Fig. 3.4 
A & B).   
 
These results suggested that post-transcriptional regulation contributes to 
the increased expression of PUMA, either through increased protein stability or 
increased translation.  We therefore assessed the half-life of PUMA protein in 
GM compared to DM.  Myoblasts were cultured in either GM or DM, each 
supplemented with the protein synthesis inhibitor cycloheximide (CHX).  PUMA 
protein levels were then measured by Western analysis after various times.  The 
half-life of PUMA (Fig. 3.5)  was greater than 24 hours.  Thus, we have focused 
on the translational regulation of PUMA. 
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A) 
B) 
 Figure 3.3  siRNA treatment of 23A2 cells suppresses the increase in 
PUMA transcripts but does not prevent the increase of PUMA protein in 
DM. (A) Custom SMARTpool plus small interfering RNA (siRNA) to target 
mouse PUMA  was designed and synthesized by Dharmacon (Lafayette,CO). 
siRNA  (1.5 ug) was transfected into 23A2 cells in GM using RNAiFect  
Transfection Reagent (Qiagen) as described by the manufacturer’s protocol.  
siCONTROL Non-Targeting siRNAs  were included as a control. After 48 hours 
of transfection, cells were treated for 3 hours in DM. Total RNA was isolated 
from cells using TriZol (Invitrogen) and 0.5 g of total RNA was reverse-
transcribed using SuperScript III RNase H reverse transcriptase (Invitrogen) to 
produce cDNA according to the manufacturer’s protocol. Silencing was 
monitored at the mRNA level by Real-time PCR. (B) Western blot analysis using 
anti-PUMA and anti-actin antibodies. This is a representative of 4 independent 
experiments. Error bars represent mean + SEM from triplicate samples.  
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B) 
Figure 3.4 Actinomyocin treatment of 23A2 cells does not prevent the 
increase of PUMA protein in DM.  Cells were plated at equal density  and 
the next day switched to fresh GM or DM in the presence or absence of 
actinomycin D. (A) Total RNA was isolated from cells using TriZol (Invitrogen) 
and 0.5 g of total RNA was reverse-transcribed using SuperScript III RNase 
H reverse transcriptase (Invitrogen) to produce cDNA according to 
manufacturer’s protocol.  mRNA levels quantified by Real-time PCR. (B) 
Western blot analysis using anti-PUMA and anti-actin antibodies. This is a 
representative of 3 independent experiments. Error bars represent mean +  
SEM from triplicate samples.  
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Figure 3.5 PUMA Protein has a half-life greater than 24 hours. 23A2 
Cells were plated at equal density the next day switched to fresh GM in 
the presence of 100 g/ml of cyclohexamide. Lysates were collected at 
various time points as indicated.  Western blot analysis was performed 
using anti-PUMA and anti-actin antibodies. This is a representative of  
two independent experiments. 
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PUMA protein is translationally regulated 
 
To show that increase translation contributes to the observed increased PUMA 
expression in DM,  23A2 cells were starved in cysteine/methionine-free PRMI 
media for a brief time and pulsed with 35S-methionine in the presence of 
actinomycin D, either in the presence or absence of 10% dialyzed serum for 3 
hours. Immunoprecipitation of PUMA was performed on precleared lysates using 
a rabbit polyclonal antibody against PUMA coupled to an immunoprecipition 
matrix. The 35S-labeled precipitated PUMA protein was eluted from the resulting 
immunocomplex and analyzed by electrophoresis on a 12% SDS-polyacrylamide 
gel. Fig. 3.6 shows enhanced incorporation of the label, indicative of new PUMA 
protein synthesis in the absence of serum. Further, this enhancement was not 
affected by the presence of actinomycin D.  This is consistent with the observed 
increase in steady-state levels of PUMA protein in DM even when the increase in 
PUMA mRNA is blocked and suggests that translational regulation of PUMA is 
the mechanism responsible for increased expression of PUMA protein. 
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Figure 3.6 PUMA expression is translationally regulated  23A2 cells 
were plated at equal density and preincubated with media free of cysteine 
and methionine. Actinomycin D treated 23A2 cells were then labeled with 
35S-meth in the presence or absence of 10% dialyzed serum. PUMA 
protein was immunoprecipited as described under “Experimental 
Procedure” from lysates treated with GM (growth factor) or DM 
(differentiation) medium. Immunoprecipited 35S-labeled PUMA was loaded 
on a 12% SDS-PAGE gel and the band corresponding to 35S-labeled 
PUMA was visualized by a Typhoon scanner. Data shown is 
representative of two independent experiments. 
PUMA
GM DM
Immunoprecipitation
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PUMA translation is regulated at initiation step 
  
In order to determine if the translation of PUMA is enhanced at the level of 
translation initiation, we performed ribosomal profiling. Cytoplasmic extracts of 
23A2 cells incubated in GM or DM were layered, after treatment with 0.1 mM 
cycloheximide, on a 5-50% sucrose gradient followed by centrifugation.  
Gradients were then fractionated with continuous monitoring at 260 nm using an 
ISCO fractionator.  Analysis of ribosomal profiles reveals an inhibition of total 
protein synthesis in DM as indicated by smaller polysome peaks and a higher 
80S peak (Fig. 3.7). Furthermore, it suggests that initiation attenuation is 
responsible for this global decrease in translation. Analysis of PUMA mRNA 
across the gradient by Real-time PCR using PUMA specific primers reveals 
differential distribution of PUMA mRNA levels along polysomes in GM versus 
DM. As previously reported, an increase in translation initiation of a specific 
mRNA is indicated by an increase in its association with polyribosomes (85). In 
agreement with this, our data indicates that more PUMA mRNAs are associated 
with polysomes in the absence of serum and hence more PUMA mRNAs are 
being actively translated. As a control, we also determined the distribution of 
mRNAs are actively translated and therefore more GAPDH mRNAs are 
associated with polysome fractions, giving a similar distribution to that of PUMA 
mRNAs in DM. Removal of serum reduces the association of GAPDH mRNAs 
with polysomes consistent with its cap-dependent mode of translation initiation.  
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GAPDH mRNA distribution along polysome fractions
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A) 
B) 
Figure 3.7 Translational increase in PUMA expression occurs at initiation 
step. A) Polysome profiles of mRNAs in 23A2 cells in presence and 
absence of serum  Lysates from 23A2 cells in presence and absence of 
serum were separated by centrifugation over a 5-50 % linear sucrose gradient. 
Fractionation of gradients was performed  with the absorbance monitor set at 
260 nm. 25 fractions were collected. RNA was collected from each fraction 
using TriZol reagent (Invitrogen) as per the manufacturer’s instructions. B)  
PUMA mRNAs and GAPDH mRNAs are translocated to polyribosomal 
fractions in the absence or presence of serum respectively RNA from 
each of the two adjacent fractions were combined and distributions of PUMA 
and GAPDH mRNAs were analyzed by real-time PCR using PUMA or GAPDH 
specific primers. Results are representative of triplicate samples from two 
independent experiments. Error bars represent mean + SEM from triplicate 
samples. C) Graph bars representing total polyribosomes for PUMA and 
GAPDH in the presence or absence of serum. 
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Cap-dependent translation is initially decreased in DM but then recovers to 
levels comparable to that observed in GM 
We next investigated global translational regulation as a consequence of 
culture in DM. Culture in DM is equivalent to serum deprivation. Many studies 
have shown that total protein synthesis is subject to regulation by environmental 
cues and that serum deprivation results in decreased cap-dependent translation 
(86, 87).  We have discovered, however, that total protein synthesis as assessed 
through 35S-methionine incorporation is initially decreased after 3 h of culture in 
DM but recovers to levels comparable to that observed in GM after 18 hours (Fig. 
3.8).  
 
The presence of hypophosphorylated 4E-BP correlates with initial decrease 
but not recovery of cap-dependent translation 
To elucidate the molecular mechanism responsible for the global effect on 
translation in 23A2 cells, we began to investigate the phosphorylation state of 
4E-BP as a consequence of culture in DM. Hypophosphorylated 4E-BP binds to 
eIF4E and prevents formation of the 43S pre-initiation complex.  The appearance 
of hypophosphorylated 4E-BP correlated with the decrease in global translation  
after 3 hours of culture in DM (Fig. 3.9). However, hypophosphorylated 4E-BP 
persists even after 18 h of culture in DM when global translation has returned to 
levels detected in GM. Thus, the phosphorylation status of 4E-BP correlates with 
the initial decrease, but not the recovery, in global translation.  
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Figure 3.8 Global translation of 23A2 cells decreases after 3 hours 
in DM but then recovers to that level observed in GM after 18 
hours 23A2 cells were cultured in GM. The next day 23A2 cells were 
starved in cysteine- methionine-free RPMI for 60 minutes.  23A2 cells 
were then incubated with 35S-methionie (250 Ci/ml) in the presence or 
absence of 10% dialyzed serum (Hyclone). Cell lysates were prepared 
after the indicated time and equal amounts of protein were incubated 
with 500 l of NaOH at 37C for 15 minutes followed by 10% TCA 
precipitatation. Equal volume of each sample was applied on GFC filter 
paper. Each filter was washed with 5% TCA twice and 10 ml of ethanol 
then the amount of radioactivity was quantified by scintillation counter. 
Shown are results from one experiment which are representative of two 
independent experiments. Error bars represent mean + SEM from 
triplicate samples. 
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Others in our lab have also shown that PI3K activity in myoblasts cultured 
in DM initially decreased but then recovered to that found in GM (33).  It has 
been suggested that PI3K lies upstream of mTOR in other systems and signaling 
by mTOR phosphorylates 4E-BP and allows protein synthesis (41). To assess  
mTOR activation as a consequence of culture in DM, lysates prepared from 23A2 
myoblasts cultured in DM for various times were assessed for phosphorylated 
active mTOR by Western analysis. The phosphorylation status of mTOR follows 
that of AKT, suggesting that mTOR might lie downstream of the AKT signaling 
pathway. However, the recovery of AKT signaling to mTOR does not correspond 
with a recovery in hyperphosphorylated 4E-BP and corresponding loss of 
hypophosphorylated 4E-BP. Hence, we continued searching for a key 
translational regulator whose activation status corresponded to observed 
fluctuation in global protein synthesis. 
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Figure 3.9 4E-BP phosphorylation fails to correlate with the recovery of  
the global protein synthesis in 23A2 cells. 23A2 cells were plated at equal 
density and the next day switched to fresh GM or DM for the indicated time. 
Western blot analysis was performed on equal amounts of lysates with a 
phospho-specific antibody against 4E-BP (Cell Signaling) and an anti-β-actin 
antibody (SantaCruz). This is a representative of three independent 
experiments. 
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Figure 3.10  mTOR phosphorylation levels correlate with total protein 
translation and PI3 kinase activity in 23A2 cells upon culture in 
differentiation media. 23A2 cells were plated at equal density and the next 
day switched to fresh GM or DM for the indicated time. Whole cell protein 
lysate was prepared and subjected to SDS-PAGE. Western blot analysis was 
performed using an anti-phospho mTOR (Cell Signaling) antibody and 
visualized by autoradiography. Anti ß-actin (Sigma) was used as the control 
for equal loading. The results shown here are representative of three 
independent experiments.  
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De-phosphorylation of eIF2α correlates with the recovery of Cap-dependent 
translation 
Since eIF2α  phosphorylation regulates the rate of protein synthesis (7, 8), 
we next assessed the phosphorylation status of eIF2α  in 23A2 cells as a 
consequence of culture in DM by performing Western blot analysis using  a 
phospho-specific antibody to eIF2α  (Ser-51). Phosphorylated eIF2α prevents the 
exchange of GDP for GTP by eIF2B and blocks translation initiation.  
phosphorylation of eIF2α is below the level of detection in presence of serum. 
Phosphorylation can be detected as early as 30 minutes upon removal of serum 
and is maximal from 3 to 6 hours in DM (Fig. 3.11). This is in agreement with our 
previous data showing a decrease in total protein synthesis after 3 hours in DM. 
Furthermore, phosphorylation of eIF2α decreases after 18 hours in DM and this 
correlates to the recovery of global translation.   
  
To identify the kinase responsible for eIF2α a phosphorylation, we focused 
our attention on PKR. Recently, caspase-dependent activation of PKR has been 
reported. In this cleavage-induced mode of activation, cleavage of PKR at an Asp 
residue frees the catalytic domain from the control of the regulatory domain 
resulting in a free kinase domain which is constitutively active (50).   Since our 
lab has previously shown activation of caspases in 23A2 cells as a consequence 
of culture in DM, we monitored PKR cleavage by performing Western blot 
analysis using an antibody that recognizes its N-terminal domain (Fig. 3.12). We 
confirmed the cleavage of PKR in DM after 3 hours by detecting a 38 KD 
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fragment which is similar in size to the estimated fragment of the regulatory 
domain of PKR.  This 38 KD fragment is absent in GM. Since PKR activation 
coincides in time with eIF2α  phosphorylation, these results allow us to speculate 
that eIF2α  phosphorylation could be mediated by PKR activation in DM. 
Although these data suggest that caspase-mediated activation of PKR and 
subsequent phosphorylation of eIF2α in 23A2 cells might be responsible for the 
inhibition of total protein synthesis during apoptosis, future studies using caspase 
inhibitors are necessary to confirm that PKR activation and eIF2α  
phosphorylation are indeed capspase-mediated.  
 
Identification of secondary structures in 5  UTR of PUMA using MFOLD 
algorithm  
We have previously shown an increase in eIF2α phosphorylation levels 
which correlated with a decrease in total protein synthesis after switching the 
culture of 23A2 cells to DM for 3 hours. We have also demonstrated that PUMA 
protein expression levels increase under the condition of decreased global 
translation.  These data led us to hypothesize that the increase in PUMA 
expression under the condition of decreased total protein synthesis could be 
IRES-mediated.  
 
Analysis of IRES elements within the 5UTR of several viral mRNA has 
revealed several general structural features important for internal ribosomal entry 
(70, 71). We performed computational analysis to predict the possible secondary  
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 Figure 3.11 The phosphorylation status of eIF2 correlates with the 
level of total translation in 23A2 cells upon removal of serum. 23A2 
cells were plated at equal density and the next day switched to fresh GM or 
DM for the indicated time. Whole cell protein lysate was prepared and 
subjected to SDS-PAGE. Western blot analysis was performed using an 
anti-phospho eIF2 (Ser51) (Cell Signaling) antibody or anti-eIF2α 
antibody and visualized by autoradiography. Anti-ß-actin (Sigma) was used 
as the control for equal loading. The results shown here are representative 
of four experiments.  
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Figure 3.12 The appearance of active PKR fragments upon 
culture of 23A2 cells in DM correlates with the phosphorylation 
status of eIF2 and total protein synthesis. 23A2 cells were plated 
at equal density and the next day switched to fresh GM or DM for the 
indicated time. Whole cell protein lysate was prepared and subjected 
to SDS-PAGE. Western blot analysis was performed using an anti-
PKR (N-terminal 1-515 amino acid) antibody (Santa Cruz) and 
visualized by autoradiography. The results shown are representative 
of two separate experiments.  
PKR
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structures within the 5UTR of PUMA RNA. Secondary structural elements were  
generated using MFOLD algorithm (88). This method predicts RNA folds that are 
thermodynamically stable based on their minimal free energy. Using the MFOLD 
algorithm, we identified the presence of predicted secondary structures in the 5 
UTR of PUMA (Fig. 3.13).  It is suggested that the presence of such highly stable 
stem loops with a predicted ΔG value of -91 Kcal/mol in the 5UTR of PUMA 
could be inhibitory to the conventional translation initiation by scanning 
mechanism (89, 90). 
 
Competition by cap analog failed to inhibit the translation of capped PUMA 
RNA 
To test the hypothesis that PUMA protein is translated via a cap-
independent mechanism, the whole sequence of PUMA cDNA, including poly(A) 
sequence,  was cloned into the pBluescript (Stratagene) vector as described in 
Material and Methods. The resulting plasmid was linearized and subjected to an 
in vitro transcription program using the mMESSAGE mMACHINE T7 ULTRA kit 
(Ambion). The resulting capped PUMA RNA transcript was used to program in 
vitro translation reactions with rabbit reticulocyte lysate (RRL) in the absence or 
presence of increasing concentrations (0.200 m and 1 mM) of cap analog 
m7GpppG (Ambion). To monitor the inhibition of cap-dependent translation, a  
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Figure 3.13 A) Predicted 
secondary structures of PUMA 
5 UTR were generated by 
MFOLD. A strong secondary 
structure with ΔG of -91 kcal/mol 
was identified. B) Nucleotide 
sequence of structural elements 
within PUMA 5UTR.  
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ΔG -91.74 
CUGAGACGCGGCAUAGAGCCACAU
GCGAGCGGGGAGCCCAGGAGGCG
GCGGCGACACCAGCAAGCAAGCAG
CAGCAGCGGUGAUCCGGACACGAA
GACUCCAGAAGCAGCAGCAGUCAC
UGCAGUUAGAGCAGCAGGAGCAGC
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Figure 3.14 Competition by cap analog failed to inhibit the translation of 
PUMA RNA A) schematic diagram of constructs used in this experiment. B)In 
vitro translation of capped PUMA RNA in the presence or absence of 
exogenously added cap analog. pBluescript containing the entire PUMA cDNA 
and pCAT were linearized. Capped RNAs were transcribed in vitro (mMachine 
mMassage T7 transcription kit (Ambion). Capped RNA transcripts were used 
to program in vitro translation reactions with RRL in the presence of increasing 
concentrations of cap analog m7GpppG (Ambion) as indicated. Data shown 
here is representative of two independent experiments. C) quantification of 
band shown in B by a typhon scanner. 
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pBluescript vector containing the CAT enzyme was used as a positive control. 
The addition of a cap analog decreases the cap-dependent translation of CAT 
enzyme in a dose-dependent manner; however, it fails to inhibit the translation of 
capped PUMA RNA, suggesting that PUMA mRNA can be translated in a cap-
independent manner (Fig 3.14).  
 
PUMA 5-UTR functions as an IRES in a bicistronic vector in vitro  
We also determined the sequence within the 5UTR of the PUMA mRNA 
that would be sufficient to mediate IRES-dependent translation of PUMA mRNA.  
The complementary DNA sequence corresponding to the 5UTR of PUMA mRNA 
was cloned between CAT and LUC genes in a pGEM bicistronic vector 
developed by Drew & Belsham (82) (Fig 3.15A). The constructs containing either 
the full length 5UTR or full length 5UTR and additional nucleotides past the 
initiation codon were subject to an in vitro translation reaction and the translation 
efficiency of each construct was determined as the ratio of fLUC/CAT. Insertion 
of the 5UTR of PUMA resulted in an increase in the ratio of fLUC/CAT; however, 
addition of 50 or 100 nucleotides past the coding sequence resulted in an 
increase of this ratio, three to four times that observed with vector alone (Fig 
3.18C). This data is in agreement with previous published reports showing that 
sequences within the protein coding region were sometimes required for IRES 
function (91-93). 
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Figure 3.15 PUMA 5UTR shows IRES activity in vitro. A) A diagrammatic 
representation of the bicistronic control (pGEM-CAT-ICS-LUC) and PUMA 
5UTR containing vectors. B) A diagrammatic representation of region of 
PUMA cDNA tested in these bicistronic constructs. C) pGEM  bicistronic 
vector control,  harboring PUMA 5UTR and PUMA(+50) 5UTR, and 
PUMA(+100) 5UTR were each linearized and transcribed in vitro using the 
mMESSAGE mMACHINE T7 ULTRA kit (Ambion ). Capped RNA was in vitro 
translated using RRL. Radiolabeled protein was resolved on a 12% SDS-
PAGE and the amount of radioactivity was quantified. Data shown here is 
representative of two independent experiments. 
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PUMA protein expression in DM is cap-independent 
To investigate if the increase in PUMA protein levels observed after 3 
hours of culture in DM is cap-dependent, 23A2 cells were treated with rapamycin.  
Rapamycin inhibits the function of the mammalian target of rapamycin, mTOR, a 
serine/thereoine kinase responsible for phosphorylating 4E-BP (94-96). Inhibition 
of mTOR results in hypophosphorylation of  4E-BP,  which becomes active and is 
then able to inhibit the formation of the eIF4F initiation complex by sequestering 
eIF4E, thereby  blocking cap-dependent translation of mRNA (19, 40, 97).  To 
determine the concentration of rapamycin necessary to inhibit cap-dependent 
translation, we assessed the level of MyoD, a protein with half-life of 45 minutes, 
following treatment with rapamycin.  Blocking cap-dependent translation allowed 
MyoD protein levels to be reduced to nearly below detectable levels after 3 hours 
(Fig. 3.16A). We showed that the inclusion of rapamycin at a concentration 
sufficient to prevent cap-dependent translation of MyoD did not affect the 
expression of PUMA protein in DM (Fig. 3.16A).  We also showed that myogenin 
induction in DM could be inhibited by inclusion of rapamycin (Fig 3.16B). 
 
PUMA 5-untranslated region functions as an IRES in vivo 
 
To investigate whether PUMA is translated in an IRES-mediated manner 
in vivo, we used the monocitronic construct pUHD10-3/LUC in which PUMA 
5UTR and different regions past the initiation codon were each cloned in frame 
upstream of the Firefly luciferase gene. The resulting monocistronic vector, if  
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B) 
Figure 3.16 PUMA expression in DM is cap-independent. A) 23A2 cells 
were treated in the presence or absence of rapamycin (100 nM) in DM for the 
indicated time, A) total protein lysates were prepared and resolved on 10%  
 for MyoD which has a short protein half life) or 12% (for PUMA) SDS-PAGE. 
Steady state level of PUMA ,  MyoD and β-actin were determined by Western 
blot analysis using antibodies against PUMA, MyoD and β-actin, respectively 
B) Western blot analysis of 23A2 cells treated in presence or absence of 
rapamycin in DM for 12 hours. Lysates were resolved on 10% SDS-PAGE and 
immunoblot analysis was performed using anti-myogenin antibodies. Data 
shown here is representative of two independent experiments.  
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expressed, produces a monocistronic chimeric mRNA (83). To distinguish 
between scanning- dependent and independent translation initiation, we utilized 
a pUHD10-3/LUC vector that harbors a stable RNA hairpin upstream of fLUC. 
Using this vector, PUMA 5UTR was cloned downstream of the hairpin in-frame 
with the fLUC gene. 23A2 cells were transfected in GM with these monocistronic 
constructs along with a β-galctosidase expression vector.  The cells were 
switched to DM for 3 hours. Luciferase activity was determined for each construct 
and normalized to β-galctosidase to account for differences in transfection 
efficiency. Upon switching 23A2 cells to DM, the ratio of fLuc/β-gal was 
enhanced significantly if PUMA 5UTR +100 nt was inserted into this 
monocitronic vector (Fig. 3.17B); however, this ratio did not change if only 50 nt 
past the initiation codon was added to PUMA 5UTR (data not shown). In 
addition, the hairpin was effective in inhibiting cap-dependent translation as 
determined by a sharp decrease in fLUC/β-gal ratio for the control vector 
harboring the RNA hairpin (phpRF).  The presence of the hairpin, however, did 
not affect the expression of the vector harboring PUMA 5UTR indicating that 
PUMA 5UTR can support translation independent of the cap (Fig. 3.17C). The 
fact that an additional sequence from the coding region is required for IRES 
activity of PUMA in vivo also suggests the involvement of trans-acting factors in 
vivo which are absent in vitro. We performed RT-PCR analysis on RNA extracted 
from these transfected cells using Firefly luciferase specific primers (Fig. 3.17D) 
to exclude the possibility of a transcriptional increase as a mechanism 
responsible for enhanced expression of the construct harboring  the putative  
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Figure 3.17 IRES-mediated translation of PUMA A) A diagrammatic 
representation of constructs used in this experiment.A&B) 23A2 cells 
were transfected independently with monocistronic constructs along 
with a β-gal control vector as indicated. 24 hours after transfection, cells 
were switched to fresh GM or DM for 3 hours. Cell extracts were 
prepared and luciferase activities were measured according to the 
manufacturer’s instructions (Promega) and normalized to β-gal using a 
β-gal assay (Promega). D) RT-PCR analysis using RNA from 23A2 
cells transfected in GM or DM with the indicated constructs and a 
Renilla expression vector. Error bars represent mean + SEM from 
triplicate samples. 
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PUMA IRES element.  
 
PUMA 5-untranslated region mediates internal ribosome entry site-
dependent translation in vivo   
Since the standard test for detecting IRES activity utilizes a bicistronic 
vector (61),  we cloned PUMA 5UTR +100 nt of coding region from AUG into a 
pRF Vector.  In this bicistronic vector, the Renilla LUC is translated from the first 
cistron in a cap-dependent manner whereas the Firefly LUC enzyme is translated 
from the second cistron. Enhanced expression of the second cistron is only 
achieved if the intercistronic region harbors elements with IRES activity. 23A2 
cells were transfected with these bicistronic constructs separately in growth 
medium. Twenty four hours after transfection, 23A2 cells were switched to fresh 
GM or DM for 3 hours and the luciferase activity of each cistron was determined.    
Similar to results obtained using monocistronc constructs, the pRF harboring 
PUMA 5UTR in the intercistronic region displays enhanced IRES activity as 
determined by fLUC/RLUC ratio which is significant compared to pRF control 
vector (Fig. 3.18 B&C). To distinguish reinitiation from IRES activity, we cloned 
the sequence representing PUMA IRES into a phpRF vector. This vector 
contains a RNA hairpin upstream of the Renilla coding region. Addition of a 
hairpin upstream of the Renilla cistron suppressed the cap dependent translation 
as determined by a sharp decrease in Renilla luciferase expression (Fig. 3.18D). 
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Figure 3.18 5UTR of PUMA shows IRES activity in the absence of 
serum. A) Schematic representation of the constructs used in this 
experiment. B) 23A2 cells were transfected with the indicated vectors. 24 
hours after transfection, cells were switched to fresh GM or DM for 3 hours. 
IRES activities were determined as a ratio of Firefly to Renilla activities for 
each transfection.  C) The presence of the hairpin upstream of the Renilla 
cistron inhibits its cap-dependent translation in DM (phpRF) but has no 
effect on the translation of PUMA 5UTR.  D) Renilla activity is decreased 
in phpRF transfected cell as compared to the pRF control vector 
transfected cells. Error bars represent mean + SEM from triplicate 
samples. 
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However, the hairpin did not affect  Firefly luciferase expression of the bicistronic 
vector containing the PUMA IRES (Fig. 3.18C).  
 
5 UTR of PUMA does not contain elements with promoter activity 
 Recently,  it has been demonstrated that in some cases the activity that 
defined the presence of an IRES in a few bicistronic mRNAs using bicistronic 
DNA constructs was actually due to the presence of a cryptic promoter in 
intercistronic elements (98). Indeed, the 5UTR of several genes,  including 
mouse Bad and human Sno,  have been shown to possess promoter sequences 
(84, 98). It has been argued that the increase in expression of the second cistron 
could be due to production of a monocitronic mRNA transcribed from the second 
cistron (99, 100). To rule out the possibility of the presence of a cryptic promoter 
in the 5UTR of PUMA, we generated a promoterless dicistronic vector as 
described in Material and Methods by removing the simian virus 40 promoter as 
well as the chimeric intron (Fig. 3.19A). Removal of the promoter should prevent 
the false positive detection of IRES activity from the intercistronic region of this 
bicistronic construct (101).  23A2 cells were transfected with these promoterless 
bicistronic constructs with or without PUMA 5UTR cloned into their intercistronic 
region.  No enhancement of the second cistron was observed even when the 
PUMA IRES element was present in the construct (Fig. 3.19).  Furthermore, 
switching the cells to DM failed to activate the IRES element. These observations 
ruled out the possibility of the existence of a promoter sequence in 5UTR of 
PUMA. 
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Figure 3.19 5UTR of PUMA  does not contain promoter elements. A) A 
diagrammatic representation of the bicitronic construct with the SV40 
promoter and chimeric intron. B) 23 A2 cells were transfected with 2 g of 
pRF(-) control vector in which the promoter was removed in addition to  pR 
5UTR F(-) vector  independently. 24 hours after transfection, 23A2 cells 
were switched to fresh GM or DM and lucifearse activities were determined 
using a Dual Luciferase Assay System (Promega). Fluc activity was 
normalized to Rluc activity for each transfection. This is representative of 
two independent experiments. Error bars represent mean + SEM from 
triplicate samples. 
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5UTR of PUMA does not contain splicing acceptor sites  
To rule out the possibility that the observed fLuc activity is due to the 
presence of cryptic splice sites within the bicistronic RNA which would generate 
monocistronic fluc RNAs in vivo, we performed RT-PCR analysis on bicistronic 
RNAs extracted from 23A2 cells in GM using three sets of primers as defined in 
Fig 3.20. This method was originally suggested by Van Eden (102) in assessing 
aberrant RNA species  by splicing produced from bicistronic DNA constructs. 
PCR products were subjected to electrophoresis on a 1% agarose gel.  
Amplification of the RNAs using these three set of primers should result in single 
bands of 524 bp, 383 bp and 161 bp. No additional PCR products of smaller size 
were detected. We also performed PCR amplification on a –RT sample to 
exclude the possibility of genomic DNA contamination.  These results provide 
further support that the 5UTR of PUMA does not contain cryptic splice sites.  
 
PUMA IRES activity is enhanced in response to etoposide treatment 
Increased PUMA expression is well documented in response to DNA 
damaging agents. Etoposide is a DNA damaging agent that activates the 
signaling pathways associated with DNA repair and apoptosis (103). Etoposide-
induced apoptosis is shown to be mediated through the intrinsic pathway and 
involves activation of p53 (104, 105). Recently, it has been reported that global 
reduction of translation in response to etoposide treatment coincides with 
increased levels of hypophosphorylated 4E-BP. This increased   
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Figure 3.20 RT-PCR analysis ruled out production of any 
aberrant RNA species from the dicistronic construct A) 
Schematic representation of the location of the primers and 
expected size of the corresponding product. B) RT-PCR analysis 
of total RNA extracted from 23A2 cells transfected with a 
bicistronic construct harboring the PUMA IRES using the shown 
set of primers. DNA (bicistronic plasmid harboring PUMA 5UTR), 
–RT (no reverse transcriptase) and RT (reverse transcriptase). 
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hypophosphorylation of 4E-BP is p53-mediated (106, 107). To assess the effect 
of etoposide on PUMA IRES activity, 23A2 cells were transfected with the 
bicistronic vector into which the PUMA IRES was cloned in the intercistronic 
region and the control vector independently. Twenty four hours after transfection, 
the cells were treated with etoposide for 8 hours in GM. Etoposide treatment of 
23A2 cells significantly enhanced the IRES-mediated translation of PUMA RNA 
as compared to the control vector (Fig 3.21).  
 
PUMA IRES functions in HeLa cells and 293T cells.  
Sequence analysis of the 5UTR of PUMA showed a 93% homology 
between mice and humans. This data prompted us to test the IRES in cell lines 
of human origin. HeLa cells and 293T cells were transfected with the indicated 
vectors separately. Twenty four hours after transfection, the expression of both 
Firefly and Renilla luciferase enzymes was determined. PUMA IRES activity is 
functional in Hela cells and 293T cells even in absence of treatment, unlike 23A2 
cells which require culture in DM or treatment with etoposide. Furthermore, the 
efficiency of the IRES as determined by the ratio of the Firefly to Renilla was 
even further enhanced in the presence of a RNA hairpin (Fig. 3.22).  
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Figure 3.21 PUMA IRES activity is increased in response to 
etoposide.  A) A diagrammatic representation of bicistronic 
constructs. B) 23A2 cells were transfected with the indicated 
vectors independently. 24 hours after transfection, cells were 
incubated with fresh GM in the presence or absence of 3 M/ml of 
etoposide or DMSO for 8 hours. Activity was determined as a ratio 
of FLuc/RLuc for each transfection. This experiment was done in 
triplicate. Error bars represent mean + SEM from triplicate 
samples. 
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Figure 3.22 The 5UTR of PUMA shows IRES activity in human 
HeLa and 293T cells. A) A diagrammatic representation of constructs 
used in this experiment. 5UTR + the first 100 nt of the coding region of 
PUMA was cloned into the intercistronic regions of the bicistronic pRF 
or phpRF vectors. phpRF vector contains a hairpin upstream of the 
Renilla coding sequence. B) HeLa cells & C) 293T cells were plated at 
equal density in 24 well plates. The next day, cells were transfected 
with 2 g of the bicistronic pRF, phpRF , pRF(5UTR of PUMA) and 
phpRF(5UTR of PUMA) vectors separately. 24 hours after transfection, 
both Firefly and Renilla luciferase activies were determined using a 
Dual Luciferase Assay System (Promega). Error Bar represent mean + 
SEM from triplicate samples. Data shown here is representative of two 
independent experiments. 
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DISCUSSION 
  We have previously documented a critical role for the pro-apoptotic Bc2 
family PUMA in the apoptosis that occurs in a subset of myoblasts induced to 
differentiate as a consequence of culture in DM (media lacking serum) (108). 
Others have documented a critical role for PUMA in the apoptosis that occurs in 
response to DNA damaging agents such as etoposide (109-111). To date, the 
known regulation of PUMA expression has been at the level of increased 
transcription in response to the activation of the transcription factor p53 in 
response to a number of stimuli (111-113).  We report herein the novel cap-
independent translation of PUMA and we have identified the IRES element in the 
PUMA RNA. Further, we have shown that this IRES element facilitates 
translation in myoblasts cultured in DM (media lacking serum) or treated with 
etpopside.  
 
  It is well documented from studies in other systems that culturing cells 
without serum leads to a decrease in total protein synthesis and inhibition of cap-
dependent translation in serum starved cells can in part be responsible for this 
decrease (114-116). We too observe a decrease in total protein synthesis in 
skeletal myoblasts cultured in DM (media lacking serum). However, in skeletal 
myoblasts, culture in DM leads to apoptosis in a subset of cells. The onset of 
apoptosis is likewise associated with inhibition of global translation  (86, 117). 
This regulation has been explained in part by caspase-dependent cleavage of a 
number of initiation factors involved in cap-dependent translation (86, 114, 118, 
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119). Since the decrease in total protein synthesis that we observe coincides with 
the onset of apoptosis, at this time we cannot distinguish between a decrease in 
protein synthesis in all cells or a decrease in protein synthesis in only those cells 
destined to undergo apoptosis.  
 
Interestingly, while we initially detect a decrease in total protein synthesis 
with maximal inhibition after 3 hours of culture in DM, this inhibition recovers after 
18 hours of culture in DM to levels of synthesis comparable to that detected in 
growth media (GM). At this time, there are no remaining apoptotic cells. Thus, 
there are at least three possible explanations for the recovery of protein 
synthesis.  Firstly, it is possible that only the apoptotic cells underwent a 
decrease in total protein synthesis. Alternatively, it is possible that the entire 
population initially displayed a decrease in  protein synthesis and that this 
recovered with time due to the auto secretion of insulin like growth factor I (IGF-
I). An increased secretion of IGF-I during differentiation is well documented (120, 
121). Finally, it is possible that a combination of these possibilities is responsible 
for the observed levels of total protein synthesis.  
 
Several key molecules are known to regulate translation. Serum-induced 
phosphorylation of 4E-BP allows translation initiation by preventing its 
association with eIF4E (20, 28, 40, 60, 122-128).  Using a phosphospecific 
antibody against 4E-BP, we demonstrated that the appearance of 
hypophosphorylated 4E-BP correlated with the decrease in global translation 
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after 3 hours of culture in DM; however, hypophosphorylated 4E-BP persisted 
even when global translation was recovered after 18 hours of culture in DM.  
 
Serum-induced phosphorylation of 4E-BP is mediated by PI3K/Akt/mTOR 
signaling in other system (122-128). Signaling by PI3 kinase is also required for 
skeletal myoblast differentiation.  Specifically, treatment with LY294002 (the PI3K 
inhibitor) blocks the increase in myogenin mRNA (129).  In correlation with 
results obtained from our studies on global translation, we have determined that 
PI3K signaling to Akt decreases after 3 hours in DM and recovers by 18 hours 
(130). Further, herein we report that mTOR activity similarly decreases after 3 
hours in DM and recovers by 18 hours (unpuplished). Although the suppression 
of PI3K/Akt/mTOR signaling concomitant with culture in DM and the onset of 
apoptosis could explain the decrease in 4E-BP phosphorylation and resulting 
decrease in total protein synthesis, the persistent hypophosphorylation status of 
4E-BP in DM could not be explained by the recovery of PI3K/Akt/mTOR 
signaling.   
 
eIF2 is another initiation factor whose phosphorylation is known to impair 
translation initiation (44, 131).  Our kinetic analysis of eIF2α phosphorylation 
demonstrated that the phosphorylation status of eIF2α correlates with the 
decrease and  recovery of global translation.  In our attempt to identify the kinase 
responsible for eIF2α phosphorylation, we showed that PKR cleavage, indicative 
of its activation (50, 118), is detected in 23A2 cells as a consequence of culture 
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in DM. Although these data suggest that caspase-mediated activation of PKR 
and subsequent phosphorylation of eIF2α in 23A2 cells might be responsible for 
the inhibition of total protein synthesis during apoptosis, future studies using 
caspase inhibitors are necessary to confirm that PKR activation and eIF2α 
phosphorylation are indeed capspase-mediated. Nonetheless, even if caspase-
mediated cleavage and activation of PKR is confirmed to mediate the 
phosphorylation of eIF2α, the mechanism responsible for the decrease in 
phosphorylation of eIF2α and the recovery of global translation remains to be 
determined since cleaved PKR persists.  Interestingly, recent reports suggest the 
involvement of mTOR in eIF2α phosphorylation. It has also been shown that 
GCN2 phosphorylates eIF2  in yeast in a rapamycin-depdent manner (132). 
Therefore, future work is necessary to determine the extent of GCN2 activation 
as a consequence of culture in DM and to explore the role of GCN2 in the 
phosphorylation of eIF2α.   
 
To our knowledge, we are the first to report the IRES mediated translation 
of a BH3-only proapoptotic Bcl2 family member. Nonetheless,  IRES activity has 
been discovered in several other molecules involved in apoptosis such as such 
as XIAP (133),  Apaf-1 (134) and cMyc (135). However, the activation of these 
IRESs during apoptosis is specific to the apoptotic stimuli and the cell type (64).  
For instance, it was shown that Apaf-1 translation, which is constitutively IRES-
mediated, was only enhanced in cell lines of neural origin or in response to 
genotoxic stress (136). This differential activity of IRES elements with respect to 
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cell type and stimuli are attributed to the presence of cell specific trans-acting 
factors (ITAFs), which in turn are subject to regulation by internal or external 
stimuli (73).  
 
Thus, the requirement of an additional 50 nucleotides downstream of the 
AUG for PUMA IRES activity in vivo implies that there are cell-specific trans-
acting factors that can regulate the activity of this IRES (136). We believe that 
tissue specific ITAF expression can also explain our result of enhanced PUMA 
IRES activity in HeLa and 293 T cells even in the presence of serum.  PTB is an 
ITAF that is known to be associated with many cellular IRES-containing mRNAs 
during apoptosis. PTB is highly expressed in HeLa cells as compared to other 
cell type (137). Future studies are necessary to identify the minimal IRES 
element in PUMA mRNA to identify the ITAFs associated with this PUMA IRES 
and to investigate their possible regulation in response to culture in DM or 
treatment with etoposide.  
 
 Although our analysis indicates that PUMA translation can occur under 
compromised conditions where cap-dependent translation is inhibited, we cannot 
at this point speculate whether PUMA translation utilizes both cap-dependent 
and IRES-mediated translation during apoptosis or if PUMA translation is solely 
IRES mediated under these conditions.  
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In other cell types, etoposide treatment results in the activation of the 
transcription factor p53 (138). Translational regulation in response to etoposide in 
other cell types has been reported and involves an increased level of 
hypophosphorylated 4E-BP.  It has been suggested that p53-mediated pathway 
might be responsible for modulation of 4E-BP phosphorylation in response to 
etoposide (107, 139); however, the exact mechanism is not understood.  We 
have previously shown, however,  that p53 does not play a role in skeletal 
myoblast apoptosis in response to serum deprivation (108).  Furthermore, we 
have determined a role for MyoD in the increase of PUMA expression in 
response to etoposide (T. Harford, unpublished). These data allow us to 
speculate that MyoD might be responsible for the increase in the PUMA IRES 
activity in response to culture in DM or treatment with etoposide. It is unlikely that 
a role for MyoD in the regulation of translation involves its ability to function as a 
transcription factor since we have shown that increased translation of PUMA is 
detected in the presence of actinomycin D. Several p53 mediated events are 
independent of its transcriptional activity (140). Future studies are required to 
determine the role of MyoD in this process.  
 
 
 
. 
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VI. SUMMARY 
 
Programmed cell death (apoptosis) is induced concomitant with the induction of 
differentiation in skeletal myoblasts (1, 2). Skeletal myoblast transplantation is a 
potential treatment for muscular dystrophies (3), acute myocardial infarction (4) 
and chronic end-stage heart dystrophies (5). Transplanted myoblast survival 
rates remain low despite great advances in stem cell therapy (3). Thus, 
identifying therapeutic targets for manipulation to block apoptosis associated with 
differentiation might improve efficacy of myoblast transfer. Herein we report a 
functional role for increased PUMA expression in the release of cytochrome C 
and apoptosis in skeletal myoblasts. By modulation of PUMA expression we 
showed, for the first time, that we can successfully abrogate apoptosis without 
affecting differentiation. These findings could be significant in the utilization of 
PUMA as a therapeutic target in the effort to suppress myoblast apoptosis and 
increase the efficacy of myoblast transfer. Therefore, the assessment of 
survivability of PUMA -/- satellite cells in myoblast transfer should be considered. 
We speculate that myoblasts derived from satellite cells deficient for PUMA may 
improve the regenerative potential of myoblast stem cells for the purpose of the 
cell therapy. 
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PUMA is involved in mitochondrial mediated apoptosis in response to a 
vast number of stimuli in a p53-dependent and independent manner (6). While 
exogenous PUMA expression induces apoptosis in a number of human cancer 
cells (7, 8), its deletion has been shown to abrogate apoptosis in response to 
hypoxia, p53 signaling and DNA damaging agents (9). Impairment of apoptosis 
renders cancer cells resistant to chemotherapy and radiation therapy. In many 
cases this resistance is attributed to the p53 status of the tumors (10). 
Modulation of PUMA expression has been shown to restore the therapeutic 
response of cancer cells to anticancer agents, particularly when combined with 
DNA-damaging agents (11). Our findings suggest that PUMA is translated in a 
cap-independent manner using an IRES element in its 5UTR. We showed that 
PUMA is synthesized under compromised conditions where total protein 
synthesis is inhibited.  Exploring the molecular mechanism(s) responsible for this 
IRES-mediated translation will identify additional therapeutic targets.  We believe 
that this selective translation as well as tissue specific expression of translational 
factors will allow more precise manipulation of PUMA in anticancer therapy 
regardless of p53 status.  
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